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ABSTRACT 
 
 
 
Renal cell tumors encompass a heterogeneous group of neoplasms, with distinct 
clinical, morphological, genetic and epigenetic features. Despite molecular similarities, 
revealed by large multilevel comparative studies, these molecular differences might 
portend distinct prognosis and dissimilar response to targeted therapies. Both genetic 
and epigenetic events may disrupt the main cellular pathways altered in clear cell renal 
cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma and 
oncocytoma. Despite epigenetic alterations – as gene promoter hypermethylation, 
histone oncomodification and altered miRNAs expression – have been described as 
promising biomarkers for detection and discrimination among different renal cell 
tumors as well as prognostication, validation in clinical series is still lacking, precluding 
its translation to the clinical setting. 
Thus, the main aim of this Thesis was to assess the clinical usefulness of epigenetic-
based biomarkers (mainly promoter methylation and histone modifying enzymes 
expression) in renal cell tumors, especially their diagnostic and prognostic value. 
Concerning methylation profile of renal cell tumors, a panel comprising the promoter 
methylation levels of OXR1 and MST1R was found to be a highly sensitive and specific 
diagnostic biomarker for renal cell tumors (98% sensitivity, 100% specificity) and for 
clear cell renal cell carcinoma (90% sensitivity, 98% specificity). Moreover, MST1R 
promoter methylation was associated with transcription regulation in renal cell 
tumors, and MST1R expression was associated with prognosis. 
 xviii 
 
Regarding histone modifying enzymes, SMYD2, SETD3, NO66, SETDB2 and RIOX2 
(histone demethylases or methyltransferases) were identified as differentially 
expressed in renal cell tumors and validated in a cohort of 160-cases as well as in TCGA 
database. Moreover, low SMYD2, SETD3 and NO66 expression levels were associated 
with shorter disease-specific survival, and low SMYD2, SETD3, NO66 and SETDB2 with 
shorter disease-free survival (in multivariable analysis). RIOX2 expression level was also 
associated with the development of metastasis during follow-up. 
In conclusion, epigenetic alterations constitute promising diagnostic biomarkers, as 
promoter methylation and microRNAs, and promising prognostic biomarkers, as 
histone modifying enzymes, for clinical management of renal cell tumors. Additional 
assessment in large multicenter trials is needed to support clinical implementation of 
these biomarkers. 
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RESUMO 
 
 
 
Os tumores de células renais compreendem um grupo heterogéneo de neoplasias, 
com características clínicas, morfológicas, genéticas e epigenéticas distintas. Apesar 
das semelhanças a nível molecular, reveladas por estudos comparativos, as diferenças 
moleculares podem condicionar diferentes prognósticos e resposta diferente a 
terapias dirigidas. Tanto mecanismos genéticos como processos epigenéticos podem 
alterar as principais vias de sinalização celular desreguladas nos carcinomas de célula 
renais de tipo célula clara, papilar, cromófobas e em oncocitoma. Apesar de as 
alterações epigenéticas – como a hipermetilação do promotor de genes, 
oncomodificação de histonas e expressão alterada de microRNAs – terem sido 
descritas como biomarcadores promissores para a deteção, discriminação e avaliação 
de prognóstico em tumores de células renais, não existe validação extensa em séries 
clínicas, impedindo a sua utilização em contexto clínico. 
Assim, o principal objetivo desta Tese foi determinar a utilidade clínica de 
biomarcadores baseados em alterações epigenéticas (em especial hipermetilação do 
promotor e alteração da expressão de enzimas modificadoras de histonas) em tumores 
de células renais, nomeadamente o seu valor como biomarcadores de diagnóstico e 
prognóstico. 
Em relação ao perfil de metilação dos tumores de células renais, um painel constituído 
pelo nível de metilação do promotor de OXR1 e MST1R mostrou ser um biomarcador 
de diagnóstico com elevada sensibilidade e especificidade na identificação de tumor de 
células renais (sensibilidade de 98% e especificidade de 100%) e de carcinoma de 
 xx 
 
células renais de tipo célula clara (sensibilidade de 90% e especificidade de 98%). 
Adicionalmente, o padrão de metilação do promotor do gene MST1R foi associado à 
regulação da transcrição em tumores de células renais, e a expressão de MST1R foi 
associada ao prognóstico. 
Relativamente às enzimas modificadoras de histonas, o nível de expressão de SMYD2, 
SETD3, NO66, SETDB2 e RIOX2 (histonas desmetilases ou metiltransferases) foi distinto 
em tumores de células renais diferentes, resultado este validado numa série de 160 
tumores de células renais e nos casos da base de dados do TCGA. Um nível baixo de 
expressão de SMYD2, SETD3 e NO66 foi associado a uma menor sobrevivência 
específica por doença, e nível baixo de expressão de SMYD2, SETD3, NO66 e SETDB2 a 
uma menor sobrevivência livre de doença (em análise multivariável). O nível de 
expressão de RIOX2 também foi associado ao desenvolvimento de metastização 
durante o follow-up. 
Em conclusão, as alterações epigenéticas constituem-se como promissores 
biomarcadores de diagnóstico, como a metilação do promotor e a expressão de 
microRNAs, e como promissores biomarcadores de prognóstico, como a expressão de 
enzimas modificadoras de histonas, com potencial de aplicação clínica em tumores de 
células renais. Será necessária avaliação adicional em grandes ensaios multicêntricos 
para suportar a implementação clínica destes biomarcadores. 
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THESIS OUTLINE 
 
This thesis is organized in six chapters and one appendix. 
 
Chapter 1 contains an introduction to the thesis theme, including a review on renal cell 
tumor classification, main epigenetic mechanisms, and the most frequent and 
consistently described alterations in renal cell tumors, both genetic and epigenetic. 
The second part of this chapter focuses on the potential clinical application of the 
epigenetic alterations in renal cell tumors. 
 
Chapter 2 defines the aims of this thesis. 
 
Chapter 3 enumerates the experimental procedures performed by the candidate, since 
detailed description is depicted in the methods section of each study. 
 
Chapter 4 is composed of two studies on DNA methylation of renal cell tumors. The 
first describes the diagnostic significance of a panel including the promoter 
methylation level of three genes. The second explores the prognostic and functional 
role of MST1R promoter methylation. 
 
Chapter 5 is composed of two studies focusing on histone modifying enzymes. These 
two studies were performed in close collaboration with two distinct Master students 
(acknowledged as joint first authors of the respective articles) as part of their Master 
 xxvii 
 
Degree project. For the purpose of these studies, I selected cases and I was actively 
involved in performing RNA extraction from fresh frozen tissue, cDNA synthesis, 
quantitative real time PCR, data analysis and interpretation, and manuscript writing. 
The first study identified histone methyltransferases and demethylases differentially 
expressed among renal cell tumors and assessed the role of three of them as 
diagnostic and prognostic biomarkers. The second study assessed the prognostic value 
of other two histone modifying enzymes as prognostic and disease progression 
biomarkers. 
 
Chapter 6 contains the general discussion of the main results of this thesis, as well as 
the main conclusion and future perspectives. 
 
The appendix contains a study on microRNAs as diagnostic biomarkers in renal cell 
tumors, performed by a Master Degree student as part of his Master project. I 
collaborated by selecting cases, retrieving relevant information from clinical charts and 
participating in data interpretation and manuscript review. 
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1.1. CHAPTER OVERVIEW 
 
 
This chapter includes a review paper published in international peer reviewed journal: 
 Henrique R, Luís AS, Jerónimo C. The epigenetics of renal cell tumors: from 
biology to biomarkers. Front Genet, 2012; 3:94. 
 
 
Renal cell tumors encompass a heterogeneous group of neoplasms, with distinct 
clinical, morphological, genetic and epigenetic features [1, 2]. The relevance of 
molecular alterations specific for each subtype was reflected by the relatively early 
inclusion of cytogenetic features in renal cell tumor classification [3, 4]. Despite some 
molecular similarities, underscored by large multilevel comparative studies [5], these 
molecular differences might portend distinct prognosis and dismal response to 
targeted therapies [1, 6]. 
Over the last years, integrative studies revealed the molecular features of ccRCC [7], 
pRCC [8], chRCC [9] and oncocytoma [10], revealing the main cell pathways altered in 
each subtype, mostly by genetic events. These pathways were also frequently altered 
by epigenetic alterations [2], and thus it was felt that a brief review of the main genetic 
and epigenetic processes involved in each histotype tumorigenesis, in the first part of 
this chapter, was essential to highlight the relevance of epigenetic alterations in renal 
cell tumors. 
Moreover, these epigenetic alterations might be useful in renal cell tumor diagnosis 
and prognostication, which would be promising new tools for renal cell tumor 
CHAPTER 1. GENERAL INTRODUCTION 
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management, and are reviewed in the second part of this chapter, in the published 
review [11]. 
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1.2. INTERMINGLING MORPHOLOGICAL AND MOLECULAR 
FEATURES – INSIGHTS ON RENAL CELL TUMOUR 
CLASSIFICATION AND PATHOGENESIS 
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1.2.1. KIDNEY CANCER 
Kidney cancer incidence is increasing worldwide, with 338000 estimated new cases 
and 143000 estimated deaths in 2012. Incidence and mortality rates are higher in men 
and in more developed regions. Although incidence rate has been increasing in the last 
years, more in men than women, the mortality rate has been stable and even 
decreasing in most high resource countries (Northern and Western Europe, USA, 
Australia) since the 90s, more in women than men. The ratio between incidence and 
mortality is highest in Northern America, indicating a higher survival than in Africa, 
where this ratio is lowest [1]. The increasing incidence rate has been largely attributed 
to the growing number of incidental small renal tumours diagnosed due to widespread 
use of imaging techniques, mostly in high resource countries, in addition to ageing, 
obesity and smoking, which are known risk factors for the development of kidney 
cancer. The stabilization or even slightly decrease trend in mortality rate might be 
related to efficient treatment by surgery in localized cancer, as well as interferon and 
targeted therapies used mainly in high resource countries. The rising number of small 
neoplasms incidentally diagnosed, mostly in high resource countries, could also 
contribute to this mortality trend, not being clear yet if the decreasing mortality 
corresponds to a survival gain, as the prognosis of these small tumours is generally 
good and most are cured by partial nephrectomy. A higher proportion of this small 
tumours diagnosed in high resource countries, in addition to more access to targeted 
therapies, could contribute to the differences in the ratio between incidence and 
mortality observed in high resource vs. low resource countries [1].  
The vast majority (90%) of kidney cancers are renal cell tumours (RCT), arising from 
renal parenchyma. The remaining are mostly urothelial carcinomas, arising from renal 
CHAPTER 1. GENERAL INTRODUCTION 
6 
 
pelvis. Most RCT are sporadic; however some familiar forms are well documented, 
including von Hippel-Lindau syndrome, hereditary papillary renal cell carcinoma, 
familial leiomyomatosis and renal cell carcinoma syndrome and Birt-Hogg-Dubé 
syndrome [2]. RCTs are a heterogeneous group and include benign tumours, such as 
oncocytoma (5-9%); and malignant entities, called renal cell carcinomas (RCC), which 
encompass different tumour types with dissimilar prognosis [3].  
The most frequent RCC is clear cell renal cell carcinoma (ccRCC) (70-75%), which also 
have the worst prognosis among the most prevalent subtypes, followed by papillary 
renal cell carcinoma (pRCC) (15-20%), with slightly better prognosis than ccRCC. 
Chromophobe renal cell carcinoma (chRCC) is less frequent (5-7%) and presents a 
better prognosis than ccRCC and pRCC. For each subtype, the prognosis is worst in 
tumours with metastasis, which are more frequent in ccRCC and pRCC, and rare in 
chRCC [3]. Approximately 20 to 30% of all patients present metastases at diagnosis, 
and approximately 20% develop metastases after nephrectomy [2]. 
 
 
1.2.2. SPORADIC RENAL CELL TUMOURS 
1.2.2.1 Conceptual and temporal framework of renal cell tumours classification 
The first kidney tumour classifications were based on macroscopic appearance 
(Koning, in 1826) and on macroscopic and clinical feature (Rayer, in 1841). Later, in the 
beginning of the 20th century, some classifications based on the histological features 
were proposed, mostly descriptive, comprising a variable number of entities and 
mirroring the then accepted idea that renal tumours arose from adrenal remnants, 
originating the term hypernephroma [4, 5]. 
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Although it was initially thought that renal tumours derived from renal tubular 
epithelial cells, according to Robin (in 1855) and Waldeyer (in 1867) observations, after 
Grawitz description (in 1884) of small yellow subcapsular renal tumours composed by 
clear cells as being originated from intrarenal adrenal rests (whereas small papillary 
tumours originated in renal tubules) the concept of ectopic adrenal rest origin was 
generalized for all renal tumours. The controversy remained until 1959, when Oberling 
observed that clear cells from renal tumours presented ultrastructural features similar 
to renal tubular epithelial cells [5]. Latter classifications further emphasized this renal 
origin, by designating these neoplasms as “renal cell tumours”.  
Noteworthy, these descriptive classifications included benign and malignant entities, 
despite their distinction was neither straightforward nor uncontroversial, with size 
being the most widespread criteria to distinguish them, after Bell reported a low 
metastasization rate for tumours smaller than 3cm in 1928 [4, 6]. Despite reference to 
papillary tumours and to clear and granular cells was common in these classifications, 
the first WHO classification of renal cell tumours in 1981 did not include these 
morphotypes, but acknowledged the existence of large morphological variety in renal 
cell tumours.  
A seminal paper published in 1986 and latter known as “Mainz classification” set the 
basis for subsequent classification schemes [6]. Tumours were characterized 
considering cytology and architecture, the main subtypes being clear cell, 
chromophobe, chromophilic (generally with papillary architecture) and oncocytoma. 
This was the first study to recognize that granular cells could appear in all the 
described subtypes, not being an independent subtype as previously thought, and that 
sarcomatoid change is a manifestation of dedifferentiation of the remaining cancer 
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subtypes. It also included an “unclassifiable renal cell tumour” category, to prevent 
unclear cases to be classified as a defined tumour morphotype [6]. Subsequent studies 
expanded the number of identified subtypes and compared these neoplasms to renal 
tubules epithelial cells, concluding that clear cell and chromophilic cell (papillary) 
variants originated from proximal tubules, chromophobe cell from intercalated cells of 
the cortical collecting duct, oncocytoma from cortical collecting duct and Bellini duct 
variant from principal cells of the medullary collecting duct [7]. This 
pathomorphological classification was also supported by independent cytogenetical 
and molecular studies [8-10] that reported specific cytogenetic alterations for each 
morphological subtype, as depicted bellow.  
Thus, the need for integration of these molecular data and morphological criteria in a 
single classification lead to the Heidelberg/Rochester classification (1997), the first 
using simultaneously morphological [11] and cytogenetic [12] data to design a new 
classification scheme for renal cell tumours, including benign tumours as papillary 
adenoma, oncocytoma and metanephric adenoma, as well as malignant entities as 
conventional (clear cell), papillary and chromophobe renal cell carcinoma, collecting 
duct carcinoma, medullary carcinoma and renal cell carcinoma unclassified. One 
remarkable feature of this classification was the strict morphologic criteria used to 
define each morphotype, the use of genetic alterations to classify some dubious cases, 
and the definition of an unclassified category of tumours not meeting the strict 
morphological features and devoided of the typical genetic features of each subtype 
[11, 12].  
This allowed for a more precise definition and knowledge of the prognosis of the early 
defined and more frequent histotypes, and contributed for the identification, 
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characterization (clinical, morphological, genetic) and subsequent description of novel 
RCC subtypes, four of which were included in the 2004 WHO classification [13]: 
multilocular clear cell renal cell carcinoma, Xp11 translocation carcinomas, renal cell 
carcinoma associated with neuroblastoma and mucinous tubular and spindle cell 
carcinoma. 
Accumulating evidence on each subtype common and infrequent morphology, 
prognosis, genetic and epigenetic alterations, in addition to the description of several 
novel renal tumours, lead the International Society of Urologic Pathology (ISUP) to 
promote a consensus conference in Vancouver in 2012, to update the classification of 
renal cell tumours [14]. Some entities were redefined, as multilocular cystic clear cell 
renal cell neoplasm of low malignant potential and MiT family translocation renal cell 
carcinoma, that includes Xp11 translocation renal cell carcinoma and t(6;11) renal cell 
carcinoma; and five novel entities were recognized, including tubulocystic renal cell 
carcinoma, acquired cystic disease-associated renal cell carcinoma, clear cell (tubulo) 
papillary renal cell carcinoma and hereditary leiomyomatosis renal cell carcinoma 
syndrome-associated renal cell carcinoma, as well as three provisional entities. The 
Vancouver classification set the basis for the 2016 WHO classification [3], which 
includes the new entities recognized by the Vancouver classification, as well as 
succinate dehydrogenase-deficient renal cell carcinoma; and also recognizes four 
provisional entities: oncocytic renal cell carcinoma occurring after neuroblastoma 
(removed from 2004 WHO and Vancouver classification), thyroid-like follicular renal 
cell carcinoma, ALK rearrangement-associated renal cell carcinoma and renal cell 
carcinoma with (angio)leiomyomatous stroma. 
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It should be noted that each subsequent renal cell tumour classification system further 
describes more precise clinicopathological and molecular features of well established 
entities, redefines some entities based on newly available data, and incorporates new 
entities when their morphologic and genetic features are consistently reported as 
different from the recognized renal cell tumours. So, they are dynamic frameworks for 
both precise diagnostic and further clinical, genetic and epigenetic research, since a 
precise definition of tumour entities is the basis of case selection for further studies 
and allows for the identification of new diagnostic, prognostic and predictive markers, 
specific for each tumour type and potentially more useful for clinical practice.  
Several of such studies have been published, including mutation analysis, gene 
expression analysis, methylation profiling and microRNA analysis, which are 
broadening our knowledge about renal carcinogenesis, not only the role of genetic 
alterations but especially the role of epigenetic alterations. 
 
1.2.2.2 Role of epigenetic alterations in renal tumorigenesis 
1.2.2.2.1 General concepts of epigenetic deregulation and carcinogenesis 
Epigenetics, first mentioned by Waddington in 1942, was subsequently defined as 
heritable cellular information, for instance gene expression patterns, not due to 
changes in the DNA sequence [15, 16]. Epigenetic alterations comprise DNA 
modifications, histone modifications and microRNA regulation, which might change 
the gene expression pattern of cells. These alterations are closely interrelated and, 
unlike genetic changes, might be reversible, upon action of specific enzymes [17]. 
Epigenetic mechanisms are critical to embryologic development, and some epigenetic 
alterations, as histone modifications, are involved in kidney development [18]. 
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Epigenetic alterations were first recognized in cancer in 1983 [15, 16]. In parallel with 
the cytogenetic alterations, integrated in renal cell tumour classification since 1997 
[11, 12], epigenetic alterations were early recognized as frequent in these tumours 
[19-21]. It is now widely accepted that epigenetic mechanisms are pivotal to renal cell 
oncogenesis, and the amount and variety of epigenetic alterations described in RCT is 
still increasing, some of them carrying diagnostic or prognostic relevance [22].  
 
1.2.2.2.2. DNA modifications 
The most well known DNA modification is cytosine methylation in CpG dinucleotides, 
occurring at the 5th carbon of the cytosine located 5’ of a guanosine (C5-
methylcytosine; 5mC), mediated by DNA methyltransferases (DNMT). DNA regions 
with high proportion of CpG dinucleotides have been called CpG islands, and it was 
proved by 1980 that DNA methylation at CpG islands located at a gene promoter was 
associated with gene repression [15, 17]. Other more recently described DNA 
modifications are N3-methylcytosine (3mC), catalysed chemically; N6-methyladenine 
(6mA), without known mechanism of modification; and C5-hydroxymethylcytosine 
(5hmC), C5-formylcytosine (5fC) and C5-carboxylcytosine (5caC), resulting from active 
demethylation of 5mC by TET enzymes and subsequent oxidation [23]. 
The first epigenetic alteration described in cancer cells (1983) was global loss of DNA 
methylation, i.e., hypomethylation [24, 25], which may lead to the activation of gene 
expression, including that of oncogenes as HRAS or genes associated with drug 
resistance as MDR1, as well as to chromosomal instability [16], predisposing to 
abnormal recombination and facilitating deletions, translocations and chromosomal 
rearrangements [26]. Later on, in the 1990s, hypermethylation of tumour suppressor 
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genes (TSG) promoters, with associated gene inactivation, was consistently described 
for several tumours [16], including VHL promoter hypermethylation in renal 
carcinoma, in 1994 [21]. Besides CpG islands in gene promoters, methylation of other 
DNA regions was associated with gene expression regulation, as CpG shores (low 
density CpG regions near CpG islands) [27] and gene enhancers. Indeed, enhancer 
altered DNA methylation was proposed to more closely relate with gene expression 
changes than promoter methylation itself, which might be in part due to altered 
transcription factor binding [28]. Additionally, DNA methyltransferases were found to 
be commonly overexpressed in cancer [29]. 
Thus, DNA methylation has emerged as an important epigenetic modification in 
cancer: both global DNA hypomethylation and locus-specific promoter 
hypermethylation were reported as early events in tumorigenesis [26], and 
characteristic hypermethylation profiles of TSG genes were described for some cancer 
types [20]. Several genes have been reported as hypermethylated in RCC, first 
identified by a candidate-gene approach, and later by a functional epigenomic 
approach (comparing gene expression without and after treatment with demethylating 
drugs to identify genes re-expressed after treatment, which likely correspond to genes 
silenced by promoter methylation). Genomewide CpG methylation analysis platforms 
were then used to identify putative new TSG in RCC and to disclose differences in 
methylation patterns among RCT types (reviewed in [30]). For most reported genes, 
the frequency of hypermethylation was lower than 70%, and some genes identified in 
genomewide methylation platforms were not validated by more sensitive and specific 
techniques [30]. However, it was noted that hypermethylated genes in RCC were 
involved in some frequently dysregulated pathways (Tables 1-7), including WNT – β-
CHAPTER 1. GENERAL INTRODUCTION 
13 
 
catenin, SLIT-2 – ROBO1, epithelial-to-mesenchymal transition (EMT) and metabolic 
pathways; as well as in cell cycle regulation, apoptosis and angiogenesis [22, 30]. 
 
1.2.2.2.3. Histone modifications 
The DNA strand associates with proteins, named histones, to form chromatin. The 
nucleosome, considered the basic unit of chromatin organization, is formed by a 
histone octamer (two copies of H2A, H2B, H3 and H4) core, packaging 147 bp of DNA. 
Each histone has a N-terminal tail, and histone aminoacid residues might be chemically 
modified, the most frequent being acetylation, methylation or ubiquination of lysine 
residues, phosphorylation of serine residues and methylation of arginine residues. 
These modifications, forming the so-called “histone code”, are added and removed by 
specific enzymes, control gene expression, DNA replication and repair, and 
chromosome organization [15, 22, 23]. There are currently 12 chemical modifications 
and at least 130 potential modification sites at the tails of the 4 canonical and 30 
histone variants [23]. The “histone code” implies that the combination of histone 
modifications pattern entail distinct biological outcomes, as gene expression or 
repression and chromatin remodeling, partially by recruiting downstream effector 
proteins or protein complexes [17]. For instance, gene expression is associated with 
histone H3 lysine acetylation and H3 lysine 4 di and trimethylation (H3K4me2 and 
H3K4me3) in the promoter; with H3 lysines 36 and 79 methylation (H3K36me3 and 
H3K79me2) in the gene body; and with H3 lysine 27 acetylation (H3K27ac) and lysine 4 
methylation (H3K4me1 and H3K4me2) in enhancers. Conversely, gene repression is 
associated with H3 lysine 27 trimethylation (H3K27me3) and H3 lysine 9 methylation 
(H3K9me3), in the promoter, gene body (H3K9me2 and H3K9me3) and enhancer 
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(H3K9me2 and H3K9me3) [31]. Globally, histone acetylation is associated with gene 
expression, and histone methylation could be associated with gene expression or 
repression depending on the modified aminoacid. Besides these chromatin marks 
(specific chemical modifications), gene expression and chromatin structure is also 
related to chromatin features (several linked modifications and complex elements), as 
nucleosome occupancy, chromatin interactions and chromatin domains [topologically 
associating domains (TAD), lamina-associated domains (LAD), long-range epigenetic 
silencing domains (LRES), large organized chromatin K9 modifications (LOCK)] [23]. 
Several chromatin modifying enzymes have been described, the most extensively 
studied being histone acetyltransferases (HAT), deacetylases (HDAC), 
methyltransferases (HMT) and demethylases (HDM), involved in the establishment, 
maintenance or removal of covalent histone modifications, important for normal cell 
differentiation; as well as chromatin remodeling protein complexes, like SWI/SNF and 
BAF-associated complexes, recruited to condense or decondense chromatin, enabling 
gene silencing or activation, respectively [17, 22, 31]. 
In neoplastic cells, histone regulating mechanisms might be altered, not only covalent 
histone marks, but also non-covalent chromatin remodeling mechanisms as 
nucleosome positioning alterations and histone variants incorporation [17]. Indeed, 
cancer cells were found to present altered methylation patterns of H3K9 and H3K27 
associated with gene repression, and different expression patterns of histone 
modifying enzymes from normal tissue, which might differ among tumour types and 
contribute to tumour initiation and progression [15, 32].  
It is thought that the deregulation of these mechanisms is relevant for renal 
carcinogenesis, as mutations in chromatin modification and remodeling genes, like 
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PBRM1, BAP1, SETD2, KDM5C and KDM6A [33-35], which were found to be frequent in 
RCCs, only surpassed by VHL mutations (Table 2). These enzymes are involved in 
genomic integrity maintenance, cell-adhesion regulation, HIF signaling and cell cycle 
control [22].  
It should be noted that some histone modifying enzymes can also target non-histone 
proteins, and their deregulation might affect cell phenotype not only by altering gene 
activity but also other cellular proteins [23]. Moreover, chromatin modifications and 
DNA methylation are functionally linked – DNMTs participate in multiprotein 
complexes with HDACs and HMTs to repress gene expression (Polycomb-mediated 
silencing), and some CpG islands display high affinity to transcription factors (as CFP1) 
that recruit activating HMTs and prevent DNA methylation [15, 17]. 
 
1.2.2.2.4. microRNAs 
The first microRNA (miRNA) was described in 1993, and by 2001, the miRNA regulatory 
role was broadly, whereas altered miRNA expression in cancer was reported in 2005, 
and since then the number of altered miRNA and the complexity of miRNA 
deregulation networks in cancer cells has substantially increased [36-38]. miRNAs are a 
class of short (19-25bp) non-coding RNAs that bind to complementary sequences in 
mRNA, targeting them for degradation, and, thus, mediate post-transcriptional gene 
silencing. Most miRNA are encoded by specific miRNA loci, whereas approximately 
30% originate from introns of protein coding genes. The primary miRNA (pri-miRNA) 
transcribed by RNA polymerase II are cleaved in the nuclei by a protein complex of 
DROSHA (a double-stranded RNase III enzyme) and its cofactor DGCR8 to a 60-70bp 
hairpin-shaped precursor miRNA (pre-miRNA), which is exported to the cytoplasm by 
CHAPTER 1. GENERAL INTRODUCTION 
16 
 
exportin 5 (XPO5). Pre-miRNA are then processed by DICER1 (a RNase III enzyme), 
which performs an asymmetrical cleavage of the dsRNA close to the terminal loop 
sequence, producing the mature miRNA duplex with 2-nucleotide 3’ overhangs. 
DICER1 associates with TRBP, which binds to dsRNA, enhancing the fidelity of cleavage 
for a pre-miRNA subset and triggering the formation of iso-miRNAs (1 nucleotide 
longer than the regular miRNA), and physically bridges DICER1 to the Argonaute 
proteins. Mature miRNA, DICER1 and other specific proteins form the RNA-induced 
silencing complex (RISC). In RISC complex, an Argonaute protein binds one strand of 
the mature miRNA (guide strand) so that its 5’ end (seed region, between nucleotides 
2-8) is positioned for interaction with the 3’ untranslated region (3’UTR) of target 
mRNA. RISC complex binding of complementary target mRNA results in faster mRNA 
degradation due to accelerated shortening of mRNA poly(A) tail [37, 39]. It is 
considered that the complementarity between miRNA seed region and target mRNA is 
crucial for post-transcriptional regulation: perfect complementarity leads to Ago-
catalyzed cleavage of target mRNA, whereas imperfect complementarity leads to 
mRNA translation repression [38]. 
A single miRNA can target several mRNA, and distinct miRNA can target the same 
mRNA, creating complex networks. In these networks, as multiple genes can be 
simultaneously regulated by an individual miRNA, the fine-tuning by regulation distinct 
sub-networks is facilitated, and, when multiple target mRNA participate in the same 
signaling pathway, even modest inhibition of multiple targets can generate a stronger 
response than total inhibition of a single target mRNA. Interestingly, miRNA encoded 
by the same polycistronic cluster tend to target the same gene or different genes in 
the same pathway, enhancing its regulatory role. Additionally, some mRNA presenting 
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longer 3’UTRs with more miRNA target sites may constitute relevant regulation points 
in cell networks, and few miRNA are predicted to account for regulation of the 
majority of network regulation sites. Thus, it is possible that specific gene expression 
signatures could be established and maintained by a small number of miRNA [39]. It 
should also be considered that the biological effect of a specific miRNA is context-
dependent, due to differential target gene expression in different cell types, and it is 
caused not solely by the direct effect on target gene expression, but also by indirect 
changes in gene expression pattern due to miRNA targeting of transcription factors. 
Indeed, many miRNA target genes are known to be transcription factors, some 
transcription factors tend to regulate miRNA more tightly than other genes and are 
more likely to be regulated by these miRNA [39].It was described that gene expression 
changes after miRNA disruption were mostly caused by transcription alterations due to 
transcription factor regulation, more frequent and extensive than post-transcriptional 
changes [40]. Moreover, it was suggested that some miRNA could directly modulate 
gene expression, possibly by facilitating RNA polymerase binding and activity in specific 
genes, and by recruiting chromatin modifiers, crosstalking with other epigenetic 
players [17, 38]. 
Cancer cells present distinct miRNA patterns compared to normal cells, which might be 
due to alterations in miRNA expression and/or to dysregulation of miRNA biogenesis 
pathway [22, 39]. miRNA expression can be affected by the classic factors that 
influence gene expression. Indeed, miRNA genes are frequently located at fragile sites 
or genomic regions subjected to mutations (deletions, amplifications or translocations) 
in cancer [41, 42], and altered transcription factor activity can also change miRNA 
expression [37]. Additionally, miRNA may be also regulated by epigenetic mechanisms, 
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especially DNA methylation and histone modification, in a dynamic tissue-specific, 
miRNA specific and epigenetic effector specific manner [37, 38]. Only about 50% of 
miRNA genes associate with CpG islands, whereas several miRNA have been reported 
to be differentially methylated in cancer [43], and histone methylation as well as HDAC 
overexpression can alter miRNA expression [38]. Moreover, several components of 
miRNA biogenesis pathway were reported to be dysregulated in cancer: DROSHA and 
DICER expression levels can be upregulated or downregulated in different cancer 
models, DGCR8 and Argonaute proteins were reported as upregulated and XPO5 as 
downregulated in several cancers, and are globally related to an altered miRNA profile, 
distinct tumour behavior, clinical features or prognosis [37].  
In addition to miRNA deregulation, molecular mechanisms to avoid miRNA regulation 
are also present in cancer cells, as expression of mRNA isoforms with short 3’ UTR and 
consequently less miRNA binding sites, and single-nucleotide polymorphisms (SNPs) in 
miRNA genes and in genes required for miRNA biogenesis [39]. 
Deregulated miRNA in RCTs are involved in key cellular pathways, as VHL-HIF network 
(for instance, miR-30c-2-3p, miR-30a-3p, miR-210, miR-206), TGFβ and epithelial to 
mesenchymal transition (EMT) (miR-141, miR-200a, miR-200b, miR-200c), and MET 
and mTOR pathways (miR-21, miR22, miR-221, miR-222, miR-486, miR-23b-3p) (Tables 
1-7). These miRNA are altered by SNPs or promoter methylation, as well as by 
mutations in DROSHA, DGCR8 and DICER [22, 44]. Interestingly, specific miRNA are 
associated with distinct RCT subtypes [45, 46], tumour stage and grade [47], and 
prognosis [48-50], and, thus, their clinical potential in RCTs is diverse and promising 
[51].  
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1.2.2.3 Malignant tumours – renal cell carcinoma 
Because ccRCC is the most frequent RCC subtype, and early studies focused only on 
ccRCC or included series comprising several RCC subtypes but with ccRCC 
predominance, the genetic and epigenetic knowledge of this subtype is broader than 
the remaining RCT subtypes. However, in recent years, an increasing number of 
publications focusing on less frequent RCT subtypes has been noted. This allows for a 
deeper understanding on renal carcinogenesis and the comparison of molecular 
mechanism underlying each RCT morphotype. 
 
1.2.2.3.1 Clear cell renal cell carcinoma 
Although it was primordially considered that smaller and circumscribed clear cell 
tumors were benign [4], it is now well established that all enclose metastatic potential, 
which increases with the growing size of tumours for kidney confined lesions, and even 
small clear cell tumours can invade renal sinus or perinephric adipose tissue [52, 53]. 
However, it was only after the Heidelberg classification in 1997 that the “alveolar” 
clear cell adenoma was dismissed [12]. 
Morphologically, ccRCC presents acinar, solid alveolar or cystic pattern, 
characteristically with a regular network of small and delicate blood vessels. It is 
composed, in routine hematoxylin/eosin sections, by cells with distinct borders and 
mostly transparent cytoplasm due to accumulation of glycogen and lipids. Some 
smaller cells with eosinophilic cytoplasm can be observed, especially in higher grade 
areas, and an eosinophilic variant is also recognized. Nuclei range from round with 
homogeneous chromatin and inconspicuous nucleoli in low grade tumours, to larger, 
polymorphic, with coarse chromatin and prominent nucleoli in higher grade tumours 
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[3, 6, 7]. Ultrastructural features include pinocytotic vesicles, brush-border equivalents 
and basal infoldings, as proximal tubule epithelial cells [7]. Moreover, large 
mitochondria with short attenuated cristae and loose matrix are observed in variable 
number and distribution in tumour cells of the eosinophilic variant [54]. 
Besides these typical morphological features, chromosomal abnormalities at 3p12-14 
(most frequently 3p deletions) have been identified in ccRCC since the late 70s [55]. 
Subsequent studies reported its absence in other RCC subtypes, especially pRCC [8, 9, 
56], and the Heidelberg classification recognized chromosome 3p deletion as a 
characteristic genetic feature of ccRCC [11, 12]. Additional cytogenetic alterations 
were consistently described, as chromosome 5q alterations (5q22 trisomy being the 
second most frequent), and deletion of chromosomes 6q, 8p, 9p and 14q, the last 
three associated with disease progression, since its frequency is superior in larger and 
higher grade tumours [10, 12, 57]. Moreover, 1q gain was reported as more frequent 
in metastatic ccRCC [58]. CGH studies globally confirmed the alterations detected by 
conventional cytogenetics, additionally identifying loss of 13q and 17p [59].  
Interestingly, some genes now known to be altered in ccRCC are located at 
chromosome 3p, the best characterized and more frequently mutated being von 
Hippel-Lindau (VHL) gene. VHL is a tumor suppressor gene identified in the familial 
cancer syndrome von Hippel-Lindau disease [60] and its inactivation is currently 
recognized as an early and pivotal event in sporadic ccRCCs pathogenesis [61]. Both 
genetic and epigenetic alterations were described for VHL: nearly 50-75% of sporadic 
ccRCC display VHL mutation, more than 90% loss of heterozigoty and about 5-20% VHL 
promoter hypermethylation [61, 62]. 
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Comprehensive and integrative ccRCC molecular characterization confirmed VHL 
mutation as the most frequent in this histotype, and identified frequent mutations in 
PBRM1, SETD2, KDM5C and BAP1, as well as in PTEN, MTOR and TP53 [63-65]. These 
approaches have also highlighted frequently deregulated genes and altered cell 
pathways in ccRCC, and portrayed some contributory genetic and epigenetic 
mechanisms, integrating and expanding several previous reports.  
In addition to VHL-HIF1a-hypoxia pathway (Table 1), the most consistently reported 
deregulated pathways in ccRCC are the chromatin remodeling machinery, including 
SWI-SINF complex (Table 2) and PI3K-AKT-MTOR. (Table 3).  
For VHL-HIF pathway (Table 1), the most frequent alteration is VHL inactivation mostly 
by deletion or mutation, leading to HIF accumulation and consequent (over)expression 
of hypoxia-related genes. Epigenetic modulation of other components of this pathway, 
mostly by promoter methylation or miRNA altered expression, also contributes to 
pathway deregulation [22]. 
Mutations in PBRM1, SETD2 and BAP1, all located at chromosome 3p, were first 
described in 2010-2011 and confirmed epigenetic alterations as major events in ccRCC 
carcinogenesis [33-35]. Additionally, some distinct mutations have been described in 
epigenetic modulators, as SWI/SIFT components, histone modifying enzymes and DNA 
methyltransferases and demethylases (Table 2), leading to altered gene expression, 
specific histone modifications and altered DNA methylation patterns. 
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Table 1. More frequently described genetic and epigenetic events affecting the components of 
the VHL – HIF pathway. Main biological effects of each alteration are also briefly described. 
Gene 
(locus) 
Main genetic and / or 
epigenetic alteration 
Biological effect 
VHL 
(3p25.3) 
-deletion (78-90%) [63-65] 
-mutation (50-83%) [63-65] 
-promoter methylation (5-
25%) [22] 
-miR-21 and miR-92 
upregulation [66, 67] 
-component of a protein complex (also including elongin B, 
elongin C, cullin-2) with ubiquitin ligase E3 activity. 
-VHL inactivation leads to absence of ubiquitination and 
targeting to degradation of target proteins, as HIFs. 
HIF-1α 
(14q23.2) 
-deletion (45%) [63] 
-mutation (0.7%) [33, 63] 
-miR-210 [68] and miR-122 
[69] upregulation 
-miR-20b downregulation 
[70] 
-induces expression of several target genes, for instance 
VEGF, involved in hypoxic response 
-miR-210 upregulation [target genes involved in angiogenesis 
(EFNA3, PTP1B, HIF-1α), cell cycle and metabolism] [22] 
-HIF-1α increases miR-210 expression and is also a target of 
miR-210; HIF-1α targeting by miR-210 contributes to an 
oncogenic imbalance between HIF-2α and HIF-1α [22]. 
HIF-2α 
(2p21) 
-miR-30c-2 and miR-30a 
downregulation [71] 
-miR-30c-2 and miR-30a expression is induced by pVHL; loss 
of VHL leads to HIF-2α increase due to absence of 
ubiquitination and loss of miRNA targeting, contributing to 
an oncogenic imbalance between HIF-2α and HIF-1α [71] 
-miR-210 upregulation [target genes involved in angiogenesis 
(EFNA3, PTP1B, HIF-1α), cell cycle and metabolism] [22] 
VEGF 
(6p21.1) 
-miR-206 [22] , miR-106a, 
miR-20b[70] and miR-126 
[72] downregulation 
-miR-15a, miR-34a, miR-
106b upregulation [70] 
- increased expression of VEGF is pro-angiogenic 
TCEB1 
(8q21.11) 
-mutation (1-3.3%) [63, 64] 
-TCEB1 mutation is 
associated with loss of 
chromosome 8 (bialelic 
inactivation) [64] 
-component of the transcription factor B (SIII) complex, 
which activates elongation by RNA polymerase II. 
-component of the VHL complex; TCEB1 inactivation leads to 
absence of ubiquitination of VHL-bound HIF proteins [64]. 
-mutually exclusive mutations in TCEB1 and VHL [64]. 
 
Not surprisingly, a strong link between hypoxia and histone modifications has been 
disclosed [73], paralleling the two more frequently altered cellular mechanisms by 
genetic and epigenetic changes in ccRCC, and some histone modifications and altered 
histone modifying enzymes levels have been associated with ccRCC prognosis [74]. 
 
 
CHAPTER 1. GENERAL INTRODUCTION 
23 
 
Table 2. More frequently described genetic and epigenetic events affecting chromatin 
remodelers, histone modifying enzymes and DNA methyltransferases. Main biological effects 
of each alteration are also briefly described.  
Gene 
(locus) 
Main genetic / 
epigenetic alteration 
Biological effect 
SETD2 
(3p21.31) 
-mutation (4-12%) [33, 
63, 64]  
-deletion (76% ) [65] 
-histone methyltransferase, catalyzes trimethylation of lysine-36 of 
histone H3 (H3K36Me3), associated with active chromatin and reduced 
CpG methylation [22] 
-SETD2 mutation associated with loss of DNA methylation at non-
promoter regions [22, 63] 
-SETD2 loss could contribute to genomic instability (H3K3Me3 required 
to ATM and TP53 activation of DNA damage checkpoint) [22] 
BAP1 
(3p21.1) 
-mutation (10%) [63, 64] 
-deletion (75%)[65] 
-miR-200b and miR-429 
downregulation [70] 
-ubiquitin C-terminal hydrolase 
-binds BRCA1 (DNA damage response), E2Fs transcription factors, E2F 
target gene promoters (cell cycle) [22] 
-BAP1-mutated tumors present E2F and PRC2 target genes 
downregulation and increased EZH2 expression [22, 64] 
-BAP1 inhibits mTOR activation by AKT; BAP1 inactivation associates 
with mTOR activation [22] 
KDM5C / 
JARID1C 
(Xp11.22) 
-mutation (3.4-7%) [33, 
63, 64] 
-deletion (54%) [65] 
-histone demethylase (H3K4Me3 demethylase), inhibits target genes by 
removing the active chromatin mark H3K4Me3 [22] 
-induced by HIF; may be involved in regulating HIF target genes’ 
expression levels [22] 
KDM6A / 
UTX 
(Xp11.3) 
-mutation (1-3%) [33, 63]  -histone demethylase (H3K27Me3 demethylase), removes the 
repressed chromatin mark H3K27Me3; KDM6A loss of function might 
lead to gene downregulation [22] 
SIRT1 
(10q21.3) 
-miR-34a upregulation 
[70] 
 
DNMT3B 
(20q11.21) 
-miR-148a upregulation 
[70] 
-alteration in DNA methylation 
TET2 
(4q24) 
-mutation (6%) [64]  
-deletion (10%) [64] 
-miR26a downregulation 
[75] 
-alteration in DNA demethylation 
-histone O-GlcNAcylation during gene transcription [64] 
SWI/SNF complex (functional interactions between distinct SWI/SNF complexes and associated co-factors regulate 
gene-specific transcription; non mutually exclusive mutations in SWI/SNF complex proteins in 58% of ccRCC [64, 
76]) 
PBRM1 
(3p21.1) 
-deletion (73-92%) [63, 
65] 
-mutation (26-33%) [63-
65] 
-regulates expression of genes involved in cell proliferation (p21), cell 
adhesion and cell signaling (E-cadherin) 
-mutations (mostly inactivating) associated with p21 downregulation, 
increased cell proliferation and migration [22], and upregulation of 
hypoxia-related genes [64]. 
ARID1A 
(1p36.11) 
-mutation (2-3%) [63, 64]  
-mutation (3%)[63] 
-competition between ARID1A and other ARIDs [76] 
ARID1B 
(6q25.3) 
-deletion (20%) [64] -associated with gene repression, cooperates with ARID2 [76] 
-represses Wnt/β-Catenin signaling [77] 
ARID3B 
(15q24.1) 
-miR-125a 
downregulation [70] 
 
SMARCA4 
(19p13) 
-mutation (2%)[63]  
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Table 3. More frequently described genetic and epigenetic events affecting PI3K/AKT/mTOR 
pathway. Main biological effects of each alteration are also briefly described. 
Gene (locus) Main genetic / epigenetic 
alteration 
Biological effect 
SPINT2 (19q13.2) -methylation (30%) [78]  -inhibits activation of MET by HGF; MET 
activates mTOR through PI3K – AKT 
activation; downregulation due to 
methylation leads to activation of mTOR 
[22] 
EGFR (7p11.2) 
FGFR3 (4p16.3) 
 IGF1R (15q26.3) 
-mutation (1%) each [64] -mTOR activation through PI3K – AKT 
activation 
ERBB2 (17q12) -miR-125a and miR-125b-2 
downregulation [70] 
ERBB3 (12q13.2) -mutation (1%) each [64] 
-miR-125a downregulation [70] 
ERBB4 (2q34) -miR224 upregulation [79] 
RACK1 (5q35.3) -copy number gain (7%) [63] 
FGFR4 (5q35.2) -mutation (1%) [64] 
-copy number gain (65%) [63, 64] 
PTEN (10q23.31) -mutation (2-4%) [63, 64] 
-deletion (18%) [63] 
-miR-21 upregulation [70] 
-miR-214 and miR-494 
downregulation [70] 
-mTOR inhibition through PI3K – AKT2 
inhibition 
-loss of PTEN causes mTOR activation 
PIK3CA (3q26.32) -mutation (3-5%) [63, 64] -mTOR activation through AKT2 activation 
PIK3CB (3q22.3) -mutation (1%) [64] 
PIK3CG (7q22.3) -mutation (2%) [64] 
AKT2 (19q13.2) -mutation (2%) [64] 
-copy number gain (2%) [63] 
-mTOR activation 
RPS6KA2 (6q27) -mutation (3%) [64] -mTOR activation through TSC1/TSC2 
inhibition RPS6KA3 (Xp22.12) -mutation (1%) [64] 
RPS6KA5 (14q32.11) -miR-148 upregulation [70] 
RPS6KA6 (Xq21.1) -mutation (1%) [64] 
TSC1 (9q34.13) 
TSC2 (16p13.3) 
-mutation (2%) [64] 
-deletion (2%) [63] 
-mTOR inhibition 
SQSTM1 (5q35.3) -amplification (7%) [63] -mTOR and nuclear factor kappa-B (NF-
kB) signaling activation 
MTOR (1p36.22) -mutation (6%) [63-65] 
-miR-99a downregulation [80] 
-cell proliferation 
-HIF-regulated transcription, some EMT 
pathways in RCC, IL4 and IGF1 signaling 
[65] 
 
For PI3K-AKT-MTOR pathway (Table 3), several genes were found to be altered by 
genetic mutations, promoter methylation and/or microRNA deregulation, mostly with 
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low frequency, but cumulative alterations might be significant for ccRCC 
carcinogenesis [64]. 
 
Other frequently reported deregulated pathways in ccRCC include Wnt-beta-catenin 
(Table 4), TGFβ and EMT (Table 5), and p53 signaling, cell cycle regulation and 
apoptosis (Table 6). These pathways, similarly to PI3K/AKT/mTOR pathway, depict 
numerous epigenetic alterations, mostly promoter methylation and microRNA 
deregulation, in addition to some low-frequency genetic mutations. 
 
Table 4. More frequently described genetic and epigenetic events affecting WNT – β-catenin 
pathway. Main biological effects of each alteration are also briefly described. 
Gene (locus) Main genetic / 
epigenetic alteration 
Biological effect 
CDK8 complex -mutations in GCN1L1, 
MED12, CCNC (16%) [65] 
-CDK8 complex regulates β-catenin-driven 
transcription [65] 
MACF1 (1p34.3) -mutation and 
methylation (<11%) [65] 
-activation of Wnt/β-catenin signaling in ccRCC [65] 
SFRP1 (8p12-11.2) -methylation (50%) [78] 
-miR-34a upregulation 
[79] 
-SFRPs bind to Wnt receptor but lack 
transmembrane and cytoplasmic domain needed for 
signal transduction and prevent its binding to FZ, 
thus downregulating Wnt/β-catenin signaling; 
downregulation due to methylation leads to 
activation of Wnt/β-catenin signaling [22, 65] 
SFRP2 (4q31.3) -methylation (56%) [78] 
SFRP4 (7p14-13) -methylation (56%) [78] 
SFRP5 (10q24.1) -methylation (59%) [78] 
WIF1 (12q14.3) -methylation (76%) [78] -inhibit Wnt/β-catenin signaling by binding to Wnt 
receptor; downregulation due to methylation leads 
to activation of Wnt/β-catenin signaling [22] 
IGFBP1 (7p14-12) -methylation (35%) [78] -inhibit Wnt/β-catenin signaling by binding to LRP5, 
LRP6 and FZ (only IGFBP1) subunit of Wnt receptor; 
downregulation due to methylation leads to 
activation of Wnt/β-catenin signaling [22] 
DKK1 (10q11.2) -methylation (44%) [78]  
DKK2 (4q25) -methylation (58%) [78]  
DKK3 (11p15.2) -methylation (53%) [78]  
SLIT2 (4p15.31) -methylation (20%) [81] -SLIT2 binding to ROBO1 activates GSK-3β which 
leads to degradation of cytoplasmic β-catenin and 
stabilizes β-catenin and E-cadherin interaction [22] 
ROBO1 (3p12) -methylation (27%) [81] 
CTNNB1 (3p22.1) -miR1826 
downregulation [82] 
-nuclear β-catenin location leads to upregulation of 
target genes as cyclinD1, VEGF, cMYC, cMET [22, 65] 
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Table 5. More frequently described genetic and epigenetic events affecting TGFβ-TGFR-SMAD, 
E-cadherin and EMT pathway. Main biological effects of each alteration are also described. 
Gene (locus) Main genetic / epigenetic 
alteration 
Biological effect 
FBN2 (5q23.3) -mutation (3%) [81] 
-methylation (40-53%) [81] 
-FBN binds TGFβ, preventing its binding to 
TGFR and induction of ZEB1 and SNAIl 
expression (via SMAD2-4) and subsequent 
CDH1 repression [22] 
TGFB2 (1q41) -miR-141 downregulation [70] -TGFβ activation of TGFR/SMADs/ZEB1-2 
pathway inhibits the expression od miR-200 
family and miR-30c  [22] 
TGFBR2 (3p24.1) -miR-21 upregulation [70] 
ZEB1 (10p11.22)  
ZEB2 (2q22.3) 
-miR200 family (miR-141, 
miR-200b, miR-200c) 
downregulation [22, 70] 
-miR-200 family inhibits ZEB1 and ZEB2; 
downregulation of miR-200 family reduces 
ZEB1-2 inhibition, thus increasing the 
transcriptional repression of CDH1 [22] 
CDH1 (16q22.1) -methylation (83%) [78] -pVHL loss causes HIF accumulation, which 
induces ZEB1 and SNAIL expression that 
repress CDH1 expression 
-EMT is promoted by low levels of E-
cadherin (encoded by CDH1) [22] 
PCDH8 (13q14.3) -methylation (19-62%) [81] -cell adhesion  [22] 
NRXN3 (14q24.3-q31.1) -deletion (45%) [63] 
CADM1 (11q23.3) -miR-15a upregulation  [70] 
CADM2 (3p12.1) -deletion (51%) [63] 
COL1A1 (17q21.33) -methylation (65%) [78] 
-miR-218 downregulation [70] 
-collagen family, extracellular matrix 
COL1A2 (7q21.3) -methylation (29%) [83] 
COL14A1 (8q24) -methylation (44%) [84] 
COL15A1 (9q22) -methylation (53%) [84] 
LOXL1 (15q24) -methylation (35%) [84] -establishes crosslink between collagen and 
elastin [22] LOX (5q23.1) -miR-149 downregulation [79] 
 
 
These cellular pathways interact with each other, and also with other cellular 
processes, which are also affected by additional genetic and epigenetic alterations, 
such as: 
 energy homeostasis: FLCN, methylated in 21% [78]; SDHD and ISCU1/2, targeted by 
miR-210 (upregulated) [22, 68]; UQCRH, methylated in 36% [63]; IDH2, with copy 
number gain (5%) [63]; 
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Table 6. More frequently described genetic and epigenetic events affecting p53 signaling, cell 
cycle checkpoints and apoptosis, altered in approximately 40% of ccRCC. Main biological 
effects of each alteration are also briefly described. 
Gene (locus) Main genetic / epigenetic 
alteration 
Biological effect 
ATM (11q22.3) -mutation (2-3%) [63, 64]  
-copy number gain (28%) [65] 
-p53 activation through CHEK2 [64] 
CHEK2 (22q12.1) -mutation (1%)[64] -p53 activation [64] 
TP53 (17p13.1) -mutation (3%)[64], (2%)[63] 
-miR-125a downregulation [70] 
-induction of apoptosis, senescence, cell 
cycle arrest, DNA repair and changes in 
metabolism  [64] 
CDKN1A -miR-21[68] and miR-106a [70] 
upregulation 
-cell cycle regulation 
CDKN2A (9p21.3) -deletion (16%)[64], (32%)[63] 
-methylation (11%)[81] 
-cell cycle regulation 
CCNB2 (15q22.2) -mutation (1%)[63] -cell proliferation 
CCND1 (11q13.3) -miR-155 [68], miR-16-2, miR-
34a, miR-503[70] upregulation 
-cell proliferation 
CCNF (16p13.3) -miR-210 upregulation  [22] -cell cycle regulation 
MDM2 (12q15) -mutation (1%)[64] 
-miR-192, miR-194, miR-215 
downregulation [85] 
-p53 inhibition [64] 
MDM4 (1q32.1) -copy number gain (14%) [63] -p53 inhibition [64] 
MYC (8q24.21) -copy number gain (23%)[64], 
(15%) [63] 
-miR-135a downregulation [86] 
 
E2F1 (20q11.22) -miR-21 and miR-106b 
upregulation [70] 
-cell cycle regulation 
E2F2 (1p36.12) -mutation (1%)[64] 
-miR-210 upregulation [22] 
 
E2F3 (6p22.3) -miR-34a upregulation [70]  
E2F6 (2p25.1) -miR-193a upregulation [70]  
p14ARF (9p21) -methylation (36%)  [78]  
p16INK4 (9p21) -methylation (10%)  [78]  
RASSF1 (3p21.31) -methylation (59%) [78] -regulates cyclin D1 degradation during 
metaphase and G1/S phase (inhibits 
proliferation) and activates apoptosis in 
response to DNA damage via ATM or JNK 
pathways [22] 
BCL2 (18q21.33) -miR-15a, miR-15b, miR-16-2, 
miR-34a upregulation [70] 
-anti-apoptotic activity 
APAF1 (12q23) -methylation (98%) [78] -apoptosis initiation (p53 signaling 
pathway) 
DAL1/4.1B (18p11.3) -methylation (45%) [78]  
DAPK (9q34.1) -methylation (38%) [78] -apoptosis induction 
MCL1(1q21.2) -miR-204 downregulation [72] 
-miR-15a, miR-193a upregulation 
[70] 
-anti-apoptotic activity; induced by PI3K 
signaling 
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 ubiquitination: besides VHL, BAP1 and CUL7 alterations [34], KEAP1 was found to be  
mutated in 4.7% of cases [64];  
 mRNA processing: QKI, deleted in 28%  [63], and other genes involved in the later 
steps of splicing, as the release of introns (for example DHX38, DHX9, FUS, GTF2F2, 
HNRNPM, PCBP1, PRPF4, SNRPG, YBX1), 3’ end processing machinery (CPSF2, 
PAPOLA, PCF11) and mRNA export to the cytoplasm (AAAS, NUPs, RANBP2, RBM8A, 
SEH1L) [64];  
 JAK/STAT pathway: JAK2, with copy number gain (3%) and targeted by miR-135a-2 
downregulation [70]; 
 carcinogen-induced damage and drug resistance mechanisms: FHIT, deleted in 80%  
[63] and methylated in 53% [78]; ABCA13, mutated in 45% [65]; MDR1, methylated 
in 87% [78]. 
 
These altered pathways are associated to changes in ccRCC gene expression. Indeed, 
distinct gene expression patterns were disclosed between VHL-mutated and wild-type 
(105 genes, involved in disulfide bonds, signaling, extracellular region and EGF-like 
domains), PBRM1-mutated and wild-type (484 genes, involved in glycoproteins, 
signaling, secretion and extracellular region), SETD2-mutated and wild-type (166 
genes, involved in prothrombin activation pathways, RAB domain proteins, zinc finger 
regions), and BAP1-mutated and wild-type (1136 genes, involved in cell adhesion, 
glycoproteins, signaling and membrane proteins)[63]. Moreover, the vast majority of 
PBRM1, SETD2 and BAP1 mutations were observed in VHL-mutated ccRCC, with 
PBRM1 mutations being mutually exclusive with BAP1 mutations [64]. Recent reports 
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suggest a multistep carcinogenic process in ccRCC, or at least in a subset of ccRCC, that 
starts with VHL inactivation and HIF signaling activation, followed by PBRM1 
inactivation and further amplification of HIF and STAT3 signaling, associated with 
increased mTOR signaling [87, 88]. Conversely, BAP mutations were associated with 
worst prognosis [64].  
These mutational patterns might be associated with distinct DNA methylation, histone 
modifications and miRNA deregulation patterns, and loss of methylation in non-
promoter gene regions has been already associated with SETD2 mutation [63, 89]. 
These changes might also associate with specific alterations in gene expression. 
Indeed, specific mRNA and miRNA clusters were identified in ccRCC [90], associated 
with mutation profile or methylation pattern [63, 91], with some consistency between 
reports [63, 92]. Additional evidence points to a correlation between gene expression 
and chromatin accessibility changes, independent of promoter methylation status. 
Interestingly, these epigenetically activated genes functionally mimic the activation of 
HIF signaling pathway, regardless of VHL mutational status [93]. 
Understanding the specific pattern of these deregulated pathways in each ccRCC, in 
addition to tumor heterogeneity [94] and mutational and epimutational evolutionary 
history of the tumor [95], is highly pertinent as it seems to portend clinical relevance in 
regard to prognosis [96], metastatic potential [47, 97] and targeted therapy selection 
and/or response [98]. 
 
1.2.2.3.2 Papillary renal cell carcinoma 
Papillary growth pattern was early described in RCTs, and the first morphological 
classifications considered tumours with papillary architecture as a distinct category of 
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either benign or malignant renal cell neoplasms, but these categories were thought to 
be solely descriptive [4]. The first evidence of differences in prognosis among RCC 
histotypes was recognized for pRCC in 1976, when a improved survival was noted for 
tumors with papillary architecture, even when only stage I tumors were compared 
[99], strengthening the recognition of pRCC as an independent entity.  
Papillary RCCs usually demonstrate pushing borders and a pseudocapsule, friable 
consistency, and are whitish-gray to yellowish or brown, sometimes with hemorrhagic 
areas, fibrosis and necrosis [3, 7]. Microscopically, tubulopapillary architecture, 
macrophages in papillae stalks and presence of abundant necrosis in some tumors with 
good prognosis were early reported [99]. Paralleling the morphological recognition of 
pRCC, called chromophilic by some authors [6], since the early 90s that chromosomal 
alterations have been consistently reported in pRCC, more frequently trisomy of 
chromosomes 7 and 17 and loss of chromosome Y, also in addition to trisomy of 
chromosomes 3q, 8, 12, 16 and 20 [8, 9, 55, 100], and this accumulating evidence was 
recognized by the Heidelberg classification [11, 12]. 
Subsequently, two morphological variants of pRCC were described, type 1 and type 2 
pRCC [101], and recognized as pRCC subtypes in the 2004 WHO classification [13]. Type 
1 pRCCs present a papillary or tubular architecture and are composed of small cells 
with pale to slightly basophilic scant cytoplasm containing free ribosomes, cisternae of 
rough endoplasmic reticulum and moderate number of small mitochondria; oval nuclei 
and inconspicuous nucleoli. Cells can be cubical or cylindrical and are arranged in a 
single layer without stratification. Edema, foamy macrophages and psammoma bodies 
might be identified in papillary cores [6, 101]. Type 2 pRCCs display larger cells with 
eosinophilic cytoplasm due to a larger number of mitochondria; large round nuclei 
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usually centrally located; prominent nucleoli; and nuclear pseudostratification [3, 6, 
101]. Nonetheless, some tumors present mixed features and the classification of 
specific cases might be challenging [102]. 
Regarding molecular characterization, comprehensive studies [103, 104] confirmed 
chromosome 7 and 17 trisomy as the most frequent cytogenetic alterations in pRCC, 
with additional cytogenetic events in a lower percent of cases, including 1p and 9p loss 
and 12q and 16q gain [105-112]. Moreover, one of the genes located in chromosome 7 
and mutated in hereditary papillary renal-cell carcinoma, the proto-oncogene MET, 
was also found to harbor somatic mutations in 13 to 17% sporadic pRCC [104, 113, 
114]. MET encodes for a receptor tyrosine kinase, and binding to its ligand - HGF - 
prompts MET receptor dimerization and activation of PI3K-AKT-mTOR pathway, 
stimulating cell growth, survival and EMT; activation of RAS-RAF-MEK-ERK pathway 
and subsequent cell proliferation; and also can activate CDC42, increasing cell motility 
[22]. Besides activating MET alterations, additional genetic and epigenetic alterations 
were reported in other components of this pathway (Table 7). Mutations in MET were 
found to be mutually exclusive with PTEN, TSC1 and MTOR mutations [104, 113].  
Similar to ccRCC, epigenetic deregulation has been implicated in pRCC tumorigenesis, 
as mutations involving chromatin remodelers and histone modifying enzymes were 
observed in pRCC, as well [102, 104, 113]: 
 Chromatin remodeling complex SWI/SNF: PRMT1, mutated in 4% [104]; ARID1A, 
mutated in 5.2% [102]; ARID2, mutated in 2.3% [102]. Pathway mutations ranging 
from 20% (type 1 pRCC) to 27% (type 2 pRCC) [104]. 
 Histone modifying enzymes: BAP1, mutated in 4.7% [102] and SETD2, mutated in 
6.5-7.5% [102, 113]; KDM6A mutation (4%) and in other KDMs (KDM1A, KDM1B, 
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KDM4B, KDM5B, KDM5C, KDM6B; mutation <1%) were also reported [104]. 
Pathway mutations ranging from 35% (type 1 pRCC) to 38% (type 2 pRCC) [104]. 
Mutations in PRMT1 and BAP1 were mutually exclusive, but PRMT1 mutations were 
found in SETD2-mutated tumors [104]. 
 
Table 7. More frequently described genetic and epigenetic events affecting MET-PI3K-mTOR 
pathway. Main biological effects of each alteration are also briefly described. 
Gene (locus) Main genetic / epigenetic 
alteration 
Biological effect 
SPINT2 (19q13.2) -methylation (45%) [78]  -inhibits activation of MET by HGF, and 
subsequent mTOR activation; 
downregulation due to methylation leads 
to mTOR activation [22] 
MET (7q31.2) altered (81% in  type 1 pRCC) by 
-mutation (7.6-17.4%) [102, 104, 
113] 
-copy number gain (7q) [104] 
-alternative splicing (5%) [104] 
-miR199a (downregulated) [115] 
-activates PI3K-AKT-mTOR and RAS-RAF-
ERK pathways [22] 
ERRFI1 (1p36) -deletion 1p36 (11.2%) [104] -inhibits EGFR (that activates mTOR) [104] 
PTEN (10q23.31) -mutation (1.5%) [104, 113] 
 
-mTOR inhibition through PI3K – AKT2 
inhibition; PTEN loss causes mTOR 
activation  [22] 
RAS (12p12.1) -mutation (1.5%) [104, 113] -activates RAF-MEK-ERK pathway, 
stimulating cell proliferation [22] 
RASSF1(3p21.31) -methylation (75%) [78] -inhibits RAS [22] 
MTOR (1p36.22) -mutation (1.5%) [113] 
-miR199a (downregulated) [115] 
-cell proliferation; HIF-regulated 
transcription, some EMT pathways in RCC, 
IL4 and IGF1 signaling [65] 
 
 
Other pathways reported to be altered in pRCC include: 
 NRF2-ARE pathway, involved in response to oxidative stress: CUL3, mutated in 4.1%; 
NFE2L2, mutated in 3.5%; KEAP1, mutated in 1.2%; FH, mutated in 0.6% [102]. 
Pathway mutation in 9.3% pRCC [104]. 
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 Hippo signaling pathway: NF2 is mutated in 4.3% of pRCC [113], always in wild-type 
MET cases [104, 113]. Pathway mutations ranging from 3% (type 1 pRCC) to 10% 
(type 2 pRCC) [104]. 
 Cell cycle regulation: CDKN2A, inactivated by mutation (0.6-1.7%) [102, 104], 
promoter methylation (6.2%) and 9p21 loss (8.1%), and targeted by miR-10b 
(upregulated) [104]. 
Several studies compared genetic and epigenetic features between type 1 and type 2 
pRCC, some focusing on differences in molecular features [105-110] and others 
suggesting a link or a progression from type 1 to type 2 pRCC [111, 112]. Regarding 
cytogenetic alterations, namely copy number alterations, some variability was noted 
among studies, possibly related to morphological case selection and differences in 
methodology [102]. Notwithstanding, trisomy of chromosomes 7 and 17 was 
consistently reported in type 1 pRCC, whereas in type 2 pRCC a more heterogeneous 
list of alterations and worst prognosis was depicted. This pattern was confirmed by 
recent comprehensive analysis of pRCC [104], reinforcing the idea that type 1 pRCC is a 
more robust genetic entity and type 2 pRCC encompasses heterogeneous tumors and 
might be further subdivided. Interestingly, separate studies identified a subgroup of 
type 2 pRCC (mostly low grade) with genetic and mRNA expression profiles more 
similar to type 1 pRCC [103, 104, 107]. This subgroup also presented a distinct 
methylation profile compared to other type 2 pRCCs, some of them with SETD2 
mutation [104]. Additionally, upregulation of miR-210 and let-7c, modulating JAK-STAT 
signaling (MYC, STAT2, STAT6) and p53, was reported in type 1 pRCC [110].  
Concerning pathway analysis, type 1 pRCC frequently (81%) presents MET (activating) 
alterations followed by mutations in chromatin modifiers (35%) and SWI/SNF complex 
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(20%); whereas in type 2 pRCC the most recurrently reported altered pathways are 
chromatin modifiers (38%), SWI/SNF complex (27%), p53 signaling (CDKN2A 
inactivation in 25%), NRF2-ARE pathway (25%), and Hippo signaling pathway (10%) 
[104]. 
Challenging the traditional view of individual gene alterations as driver events in 
carcinogenesis, one study proposed chromosome-scale copy number changes as the 
truncal driver event in pRCC, involving simultaneous altered expression of several 
genes and miRNAs and subsequent sub-clonal acquisition of distinct driver mutations, 
namely in epigenetic players, such as BAP1, SETD2 and ARID2 [102] . 
Hence, molecular data on pRCC carcinogenesis highlight the role of epigenetic 
mechanisms and the need to use strict morphological criteria and adequate ancillary 
techniques for the diagnosis of pRCC, keeping in mind the heterogeneous nature of 
type 2 pRCC, which might display some degree of morphological overlap with 
unclassified RCC displaying papillary architecture, MiT family translocation RCC and 
hereditary leiomyomatosis and RCC associated RCC [3], for instance. In addition, the 
distinct mutation, gene expression and epigenetic profiles in pRCC might be clinically 
useful as diagnostic and prognostic biomarkers, and could also be relevant for guided 
therapy selection [116]. 
 
1.2.2.3.3 Chromophobe renal cell carcinoma 
Chromophobe renal cell carcinoma was first described in humans in 1985 by Thoenes, 
as the sporadic counterpart of chemically (nitrosomorpholine)-induced renal neoplasia 
in experimental models (rats) [4, 117]. These tumors are usually large (average: 7cm), 
with pushing borders, non-capsulated, beige to brownish, and may present focal 
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grayish areas [3, 117]. Microscopically, most tumors display large solid sheets of cells 
not completely separated by vascular septa, but small nests, tubules, microcysts, 
trabeculae or focal papillae are less frequent architectural features. Large pale cells 
and small eosinophilic cells, frequently binucleated, with a perinuclear halo and 
irregular hyperchromatic nuclei with clumped chromatin can be observed [3, 117]. 
Two morphological variants were described, classic and eosinophilic chRCC. Classic 
chRCC presents predominantly large cells with light, finely reticular cytoplasm, with a 
peripheral rim of dense filamentous cytoplasm and a prominent cell membrane (“plant 
cell”-like). These larger cells usually locate at the periphery of large nests or sheets, 
and some smaller eosinophilic cells can be identified at the centre [3, 117]. 
Ultrastructurally, abundant round-elongated or invaginated microvesicles and some 
larger vesicles are seen mostly around the nucleus, and ribosomes and few 
mitochondria with variable size and shape, presenting tubulovesicular and, rarely, 
lamellar cristae, at the periphery [6, 54, 117]. Eosinophilic chRCC is predominantly 
composed of smaller polygonal cells with markedly eosinophilic and granular 
cytoplasm, and round nuclei [3, 117]. Ultrastructurally, a higher number of 
mitochondria with round to oval shape, less size variability, and tubulovesicular or 
lamellar cristae are present, as well as microvesicles admixed with mitochondria and 
other organelles [6, 54, 117]. 
Similar to other RCC, cytogenetic alterations were described in chRCC, the most 
consistently reported and most frequent being loss of chromosomes 1, 2, 6, 10, 13, 17 
and 21, each one present in more than 70% of cases and combined losses in almost all 
cases [10, 118, 119]. Additional loss of chromosome 3, 5 and 9 was described in 23-
40% of cases [119]. Comprehensive studies corroborated these results, describing loss 
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of most or entire chromosomes 1, 2, 6, 10, 13 and 17 in 86% of classic chRCC, and loss 
of chromosomes 3, 5, 8, 9, 11, 18 and 21 in 12-58% of classic chRCC. Concerning 
eosinophilic chRCC, the classic pattern of chromosomal monosomy was reported in 
53% of cases, and diploidy in 21% [120]. Concurrently, expression levels of genes 
located in these chromosomes was found to be globally decreased [119], and altered 
gene expression implicated endocytosis and vesicle mediated transport (DOCK1, 
AP1M2, HOOK2, GDI2, MAL2) in chRCC tumorigenesis [121]. Interestingly, chRCC 
present an increased number of microvesicles, as previously described, when 
compared to other RCTs [54, 117]. 
Additionally, a lower rate of exomic somatic mutations, compared to other neoplasms 
as ccRCC, was described [113, 120], as well as the presence of mutations in 
mitochondrial genome [120, 122, 123]. The main mutated genes are involved in 
metabolism and mitochondrial function, p53 and mTOR pathways [113, 120] (Table 8) 
Noteworthy, genes involved in p53 [TP53 (17p13.1), CDKN1A (6p21.2), RB1 (13q14.2)] 
and mTOR [PTEN (10q23.31), NRAS (1p13.2), MTOR (1p36.22)] pathways are located in 
chromosomes frequently (>70%) lost in chRCC [120]. Interestingly, the presence of 
mutations in mitochondrial genes was not associated with gene expression patterns 
related to loss of oxidative phosphorylation, suggesting that the increased number of 
mitochondria observed in chRCC might be a compensatory mechanism, as these 
mutations occur in heteroplasmy and are most likely inactivating [120]. 
Besides the low rate of somatic mutations, chRCC also present fewer genes with 
hypermethylation and more genes with hypomethylation compared to ccRCC [104] 
and normal renal tissue samples [124]. Both hyper and hypomethylated genes were 
found altered in less than 50% of cells within the samples, and the most frequently 
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deregulated cell networks by hypermethylation were tissue development and 
morphology (13 genes); cell signaling, molecular transport and mineral metabolism (12 
genes); and cell cycle, cell death and survival (11 genes) [124]. However, very little is 
known about epigenetic alterations in chRCC, especially compared to ccRCC. 
 
Table 8. Main altered pathways and genes described in chRCC. 
Pathway Altered gene – mechanism (% chRCC cases) 
Metabolism and 
mitochondrial function 
 
Somatic genes -PDHB [favors glycolysis over oxidative phosphorilation] – mutation (4.3%) 
[113] 
-PRKAG2 [subunit of AMPK, cell metabolism key sensor] – mutation 
(activating) [113] 
-NDUFA4 [complex I respiratory chain] – target of miR-145 
(downregulated) [120] 
-FAAH2 [lipid hydrolase] – mutation (4.3%) [113] 
-PPARGC1A [regulator of mitochondrial biogenesis] – upregulation[120] 
Mitochondrial genes 
(mutation in 20%, with 
>50% heteroplasmy) [120] 
Electron transport chain complex 1 genes (altered in 18%) 
-MT-ND5 – mutation (9.8%) [120] 
-MT-ND1 – mutation (3.3%) [120] 
-MT-ND2 – mutation (3.3%) [120] 
-MT-ND4 – mutation (3.3%) [120] 
Telomere maintenance 
and DNA repair 
-TERT [upregulation] – genomic structural rearrangements involving 
promoter (10%) [120] 
TP53 pathway -TP53 – mutation (21-32%) [113, 120]  
mTOR pathway (genomic 
targeting in 23%) [120] 
-PTEN – mutation (6.4-9%) [113, 120] 
-TSC1 – mutation (6%) [120] 
-TSC2 – mutation (6%) [120] 
- mTOR – mutation (3%) [120] 
Chromatin remodeling -ARID1A – mutation (4,3%) [113] 
 
Regarding prognosis, chRCC clinical behaviour is mostly favorable, although an 
aggressive subgroup with metastatic potential and worst prognosis exists [125]. On 
macroscopic and histological grounds, some overlap might exist between chRCC, 
mainly the eosinophilic variant, and renal oncocytoma. Together with the globally 
favorable prognosis of chRCC, these features raised the question of a possible link 
between chRCC and oncocytoma [4], and highlighted the need to find biomarkers that 
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might be useful to distinguish them [126, 127]. Indeed, considerable molecular data on 
chRCC focus on the distinction between chRCC and renal oncocytoma. Several genetic 
and epigenetic markers were found to be differentially expressed between these 
subtypes, and distinct panels were proposed to specifically distinguish chRCC from 
oncocytoma, including gene expression profiles (API1M2 / MAL2 / PROM2 / PRSS8 / 
FLJ20171 [121]; ASB1 / GLYAT / PDZK1IP1 / PLCG2 / SDCBP2 [113]; and HRPT2 / AQP6 / 
SYNGR3 [128]) and DNA methylation profiles (hypermethylation of ALCAM and TRPC4P 
in oncocytoma, and TFAP2B, HOXA9, DBC1 and CACNG7 in chRCC [124]). Additionally, 
miRNA expression was associated with prognosis (high miR-210 expression and short 
disease free survival) [129]. Nonetheless, these biomarkers did not reach routine 
implementation, likely due to lack of validation in large independent cohorts, and to 
inconsistent immunostaining pattern in clinical samples [126]. 
 
 
1.2.2.4 Benign tumours 
1.2.2.4.1 Oncocytoma 
Oncocytoma represents 5 to 9% of all renal neoplasms [3, 130], and is a benign renal 
cell tumor arising from collecting duct intercalated cells, composed of oncocytic cells 
[131]. Oncocytomas are usually solid and well circumscribed tumors, slightly lobulated, 
with a yellow-tan to mahogany brown colour and a central scar. However, limited 
infiltrative growth, focal hemorrhage and eccentric scarring may be seen [3, 7, 127]. 
Microscopically, oncocytomas present solid and nested architecture, typically with 
small nests disposed in a loose connective tissue stroma. Tumor cells are large, round, 
with indistinct borders and a densely granular eosinophilic cytoplasm, round nuclei 
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typically in the centre of the cell, and small nucleoli. Binucleated cells can also be 
observed [3, 6, 7, 127]. The cytoplasmic granular and eosinophilic appearance is due to 
the presence of round and uniform mitochondria, slightly larger than chRCC’s 
mitochondria and with prominent lamellar cristae [6, 54].  
Distinct cytogenetic alterations have been described in oncocytomas, the most 
frequently reported being loss of chromosomes 1 (partially or entirely) and Y, 11q13 
rearrangements, and chromosome 14 deletion [9, 10, 132-134]. Somatic pairing of 
chromosome 19 was also described and associated with deregulated gene expression 
within paired regions [135]. One of these genes is ELGN2, a prolyl-hydroxylase that 
regulates oxygen dependent HIF degradation. ELGN2 overexpression in oncocytomas 
increases HIF degradation and consequent downregulation of hypoxia-inducible target 
genes [135]. However, it should be kept in mind that mosaicism and a normal 
karyotype are also common in oncocytomas [8, 133]. 
Based on the pattern and frequency of these cytogenetic alterations, three 
oncocytoma groups were purposed: one with chromosome 1 loss, followed by 
chromosome Y or 14 deletion, another with translocation involving 11q13, and the 
remaining without recurrent or detectable cytogenetic alterations [133]. The existence 
of these distinct oncocytoma subtypes was also reported in a comprehensive analysis 
of oncocytoma, which identified two main subtypes of oncocytomas, one dyploid (type 
1) with translocation of 11q13 at the CCND1 locus and cyclin D1 overexpression; and 
another with loss of chromosomes 1, X or Y, and/or 14 and 21 (type 2) [136]. 
Regardless of these distinct subtypes, oncocytoma present fewer somatic mutations 
than other RCTs [113], and mutations in known cancer genes and genes mutated in 
renal cell tumors (TP53, PTEN, FLCN, VHL, FH, SDHB, SDHC, or SDHD) were not 
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detected [136]. Conversely, the main feature of oncocytoma is the presence of 
inactivating mutations in mitochondrial genes, encoded by the nuclear and 
mitochondrial genome, is thought to be an early event in tumorigenesis [136]. The 
previously described mutation in genes encoding electron transport chain complex 1 
components (MT-ND1, MT-ND4 or MT-ND5) [137], was found to be recurrent in 
oncocytoma, the most frequent (>25%) in MT-COX1, MT-COX2, MT-COX3, MT-ND4, 
MT-ND5, and MT-CYTB [136]. It was proposed that defects in mitochondrial respiration 
due to these alterations might activate p53, thus contributing to a metabolic 
checkpoint that limits tumor progression, and that are also associated with defective 
Golgi transport and autophagy, leading to the cytoplasmic accumulation of 
mitochondria, a characteristic feature of oncocytoma [136].  
Epigenetic studies on oncocytoma are scarce, with the exception of comparative 
epigenetic studies with chRCC, which identified global lower percentage of 
hypermethylation and higher percentage of hypomethylation compared to chRCC 
[124], and some genes with distinct methylation profile, still lacking independent 
validation in larger series, as previously described in the chRCC section. 
 
1.2.2.4.2 Papillary adenoma 
Papillary adenoma is the most frequent tumour originating from renal epithelial cells 
[13] and autopsy studies show increasing frequency with age, from 10% between 21 to 
40 years old, to 40% between 70 to 90 years old [3]. 
Presently, only tumours with papillary architecture are included in the renal adenoma 
category [3]. However, the first reports on RCT classified all small and circumscribed 
tumours without metastasis as renal adenomas, regardless of the architecture, even 
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though some authors described papillary and alveolar types. Although Grawitz, in 
1883, recommended that only papillary tumours should be classified as renal 
adenomas whereas alveolar clear cell tumours should be considered as derived from 
adrenal rests, most authors continued to regard all small localized tumours as renal 
adenomas irrespective of architectural pattern. A continuum between renal adenoma 
and carcinoma was postulated, and adenomas were considered the precursor lesions 
of renal carcinomas by some authors [4]. Tumour size has been established as the 
main criteria to distinguish adenomas from carcinomas, especially after Bell report in 
1938 which classified all renal tumours smaller than 3cm as adenomas regardless of its 
architecture, and this was adopted by subsequent classification systems including the 
first WHO classification (1981) [4].  
The first classification that restricted renal adenoma to papillary low-grade tumours 
smaller than 5mm was the Heidelberg classification in 1997 [11], and subsequently the 
only alteration was in the 2016 WHO classification: the maximum size allowed for 
papillary adenoma is now 15mm [3]. Moreover, papillary adenomas are cortical 
tumours, frequently subcapsular, uncapsulated and depicting papillary, tubulopapillary 
or tubular architecture. Tumour cells have pale cytoplasm, round to oval nuclei with 
minimal pleomorphism and inconspicuous nucleoli [3]. 
Papillary adenomas frequently display trisomy of chromosomes 7 and 17, and loss of 
chromosome Y, similar to pRCC, and thus, cytogenetic analysis may not distinguish 
papillary adenoma from pRCC [3].  
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1.2.3. CLINICAL POTENTIAL OF EPIGENETIC ALTERATIONS IN RENAL CELL TUMORS – RATIONALE 
Renal cell tumorigenesis is a complex process encompassing both genetic and 
epigenetic events that concurrently alter key pathogenic cell pathways [22]. Renal cell 
tumors are not a homogeneous molecular entity, and the most frequent RCTs – ccRCC, 
pRCC, chRCC and oncocytoma – present a distinct array of genetic and epigenetic 
alterations, some of them associated with prognosis or therapy response [63, 104, 120, 
136]. 
The advances in kidney cancer treatment have increasingly required an adequate 
identification of the histological type in pre-surgical biopsies, and more information 
regarding patient prognosis [138]. As epigenetic alterations are early and ubiquitous 
events in renal tumorigenesis [15, 22], epigenetic features of renal cell tumors 
constitute as promising diagnostic and prognostic biomarkers [139] that might provide 
relevant information for an early diagnosis and personalized therapeutic approach in 
patients with renal cell tumors [78, 95]. 
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1.3. THE EPIGENETICS OF RENAL CELL TUMORS: FROM 
BIOLOGY TO BIOMARKERS 
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Epigenetic alterations might provide clinically useful biomarkers for accurate detection 
of renal cell tumous (RCT), distinction among different RCT and assessment of 
prognosis, through gene promoter hypermethylation, histone modifying enzymes and 
miRNA expression analyses. These alterations might be used in a panel to distinguish 
among RCT subtypes, but validation in clinical series is still lacking, precluding its 
translation to the clinical setting. Additionally, different patterns of histone 
modifications and histone modifying enzymes among RCT types have not been fully 
explored. 
 
 
General aim 
The main aim of this thesis is to assess the clinical usefulness of epigenetic-based 
biomarkers in renal cell tumors, especially their diagnostic and prognostic value.  
We also expect that the data which derived from this project will contribute for the 
elucidation of epigenetic mechanisms involved in renal carcinogenesis, as well as for 
the implementation of new early detection, personalized treatment and personalized 
follow-up strategies in renal cell tumors. 
 
 
Specific aims 
 Systematize the patterns of epigenetic alterations, focusing on promoter 
hypermethylation and histone oncomodifications/modifying enzymes, of the 
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four most frequent renal cell tumors: clear cell, papillary and chromophobe 
renal cell carcinomas, and oncocytoma. 
 Define a biomarker panel allowing for accurate diagnosis of renal cell tumors. 
 Assess the prognostic value of promoter methylation and histone modifying 
enzymes expression in renal cell carcinoma.   
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Given that each paper has its own Methods sections, and to avoid unnecessary 
repetition, only a brief overview of the techniques performed by the candidate will be 
enumerated in this chapter. 
 
 
Patients and sample collection 
 Fresh-frozen tissue of nephrectomy specimens (tumor and normal), collected 
since 2000 to 2015, was used for this project. 
 Cases were selected after pathological review, and relevant information was 
collected from clinical files: 
 Promoter methylation analysis – 30 clear cell renal cell carcinoma, 30 
papillary renal cell carcinoma, 30 chromophobe renal cell carcinoma, 30 
oncocytoma, in a total of 120 cases; 10 morphologically normal renal 
tissue samples from nephrectomy specimens due to urothelial 
carcinoma; 
 Histone modifying enzymes – cohort #1: additional 10 cases for each 
renal cell tumor histotype, in a total of 160 cases; 10 morphological 
normal renal tissue from nephrectomy specimens due to urothelial 
carcinoma; 
 Histone modifying enzymes – cohort #2: 62 clear cell renal cell 
carcinoma, 31 with metastasis during follow-up and 31 without 
metastasis. 
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 This study was approved by the Institutional Review Board (Comissão de Ética 
para a Saúde) of Portuguese Oncology Institute – Porto, Portugal 
(CES518/2010). 
 
Cell lines and demethylating treatment 
 Culture of clear cell renal cell carcinoma cell lines – 769-P, 786-O, Caki-1 [from 
the American Type Culture Collection (Manassas, VA)]; 
 Treatment with the demethylating drug 5-aza-2’deoxycytidine for 72h. 
 
Nucleic acid extraction and cDNA synthesis 
 DNA extraction from fresh-frozen tissue and cell lines [phenolchloroform]; 
 RNA extraction from fresh-frozen tissue and cell lines [TRIzolR reagent 
(InvitrogenTM, Carlsbad, CA, USA)]; 
 cDNA synthesis [TransPlexR Whole Transcriptome Amplification Kit (Sigma-
AldrichR, St. Louis, MO, USA) and High Capacity cDNA Reverse Transcription kit 
(Applied BiosystemsR, Foster City, CA, USA)]. 
 
Methylation analysis 
 Screening of promoter methylation [EpiTect Methyl II qPCR array 
(SABiosciences, Qiagen, Frederick, MD, USA)] 
 Bisulfite treatment [EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, 
USA)] 
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 Primer design [Methyl Primer Express v 1.0 software (Applied Biosystems, 
Foster City, CA, USA)] 
 Quantitative methylation specific polymerase chain reaction (QMSP) [SYBRR 
Green technology] 
 
Expression analysis 
 Evaluation of mRNA expression level, after cDNA synthesis, by quantitative 
polymerase chain reaction using custom-made primers and commercial 
expression assays. 
 
Immunohistochemical analysis 
 Evaluation of protein expression by immunohistochemistry, using a semi-
quantitative scale for staining intensity and percentage of positive cells. 
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4.1. CHAPTER OVERVIEW 
 
The results presented in this chapter are published in international peer reviewed 
journals: 
  Pires-Luís AS, Costa-Pinheiro P, Ferreira MJ, Antunes L, Lobo F, Oliveira J, Henrique R, 
Jerónimo C. Identification of clear cell renal cell carcinoma and oncocytoma using a 
three-gene promoter methylation panel. J Transl Med, 2017; 15 (1): 149; 
  Pires-Luís AS, Vieira-Coimbra M, Ferreira MJ, Ramalho-Carvalho J, Costa-Pinheiro P, 
Antunes L, Dias PC, Lobo F, Oliveira J, Graça I, Henrique R, Jerónimo C. Prognostic 
significance of MST1R dysregulation in renal cell tumors. Am J Cancer Res, 2016; 
6(8):1799-1811. 
 
 
RATIONALE 
Promoter methylation has emerged as a promising biomarker class in urologic cancers, 
specifically in kidney tumors [1, 2]. Despite distinct patterns of methylations have been 
described for clear cell, papillary and chromophobe carcinoma, and also for 
oncocytoma [3, 4], validation in independent series is scarce and precludes its 
assessment as useful tools for clinical practice.  
Additionally, the functional implications of promoter methylation of some genes 
known to be methylated in renal cell carcinoma might be relevant for tumor 
aggressiveness and prognosis [5]. 
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MAJOR FINDINGS 
 A panel comprising the promoter methylation level of OXR1 and MST1R is a 
highly sensitive and specific diagnostic biomarker for renal tumors (98% 
sensitivity, 100% specificity) and for clear cell renal cell carcinoma (90% 
sensitivity, 98% specificity). 
 OXR1 promoter methylation level was significantly higher in high grade clear 
cell renal cell carcinoma. 
 MST1R promoter methylation was associated with transcription regulation in 
renal cell tumors, and MST1R expression was associated with prognosis. 
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4.2. IDENTIFICATION OF CLEAR CELL RENAL CELL CARCINOMA 
AND ONCOCYTOMA USING A THREE-GENE PROMOTER 
METHYLATION PANEL  
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4.3. PROGNOSTIC SIGNIFICANCE OF MST1R DYSREGULATION 
IN RENAL CELL TUMORS 
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CHAPTER 5 
 
HISTONE MODIFYING ENZYMES IN RENAL CELL TUMORS 
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5.1. CHAPTER OVERVIEW 
 
The results presented in this chapter are: 
 published in an international peer reviewed journal [Pires-Luís AS*, Vieira-Coimbra 
M*, Vieira FQ, Costa-Pinheiro P, Silva-Santos R, Dias PC, Antunes L, Lobo F, Oliveira J, 
Gonçalves CS, Costa BM, Henrique R, Jerónimo C. Expression of histone 
methyltransferases as novel biomarkers for renal cell tumor diagnosis and 
prognostication. Epigenetics, 2015; 10 (11):1033-43 (*joint first authors)]; 
 accepted for publication in an international peer reviewed journal [Ferreira MJ*, 
Pires-Luís AS*, Vieira-Coimbra M, Costa-Pinheiro P, Antunes L, Dias PC, Lobo F, Oliveira 
J, Gonçalves CS, Costa BM, Henrique R, Jerónimo C. SETDB2 and RIOX2 are differentially 
expressed among renal cell tumor subtypes, associating with prognosis and 
metastization. Epigenetics, in press (*joint first authors)]. 
 
 
RATIONALE 
Histone modifying enzymes and other epigenetic modulators, as SWI/SIFT 
components, were found to be altered in renal cell carcinoma, mostly by mutation [1, 
2], highlighting chromatin remodeling as a key component in renal tumorigenesis [3].  
Furthermore, some histone methylation marks were associated with prognosis in renal 
cell tumors [4, 5], but the expression pattern of the enzymes that methylate or 
demethylate histones remains largely unexplored, with few exceptions, as for UTX and 
JMJD3 [6]. 
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MAJOR FINDINGS 
 Identification and validation of five differentially expressed histone 
demethylases and methyltransferases in renal cell tumors – SMYD2, SETD3, 
NO66, SETDB2 and RIOX2. 
 Additional validation in TCGA dataset globally similar to our series 
 Low expression levels of histone modifying enzymes were associated with 
worse prognosis in renal cell carcinoma: 
 Low SMYD2, SETD3 and NO66 were associated with shorter disease-
specific survival (multivariable analysis) 
 Low SMYD2, SETD3, NO66 and SETDB2 were associated with shorter 
disease-free survival (multivariable analysis) 
 RIOX2 expression level was associated with the development of metastasis 
during follow-up. 
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5.2. EXPRESSION OF HISTONE METHYLTRANSFERASES AS 
NOVEL BIOMARKERS FOR RENAL CELL TUMOR DIAGNOSIS AND 
PROGNOSTICATION 
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SUPPLEMENTARY DATA 
 
 
 
 
Supplementary Figure 1. Expression levels of 52 HMTs and 29 HDMs in renal 
tissues. Gene expression was calculated using comparative CT method and the ΔΔCT 
using18S and GUSβ as endogenous control genes and RNTs as control group. Each 
sample was run in triplicate. The results presented correspond to median value of each 
group. (A) Five renal normal tissues (RNTs) and ten renal cell tumors (RCTs). (B) Five 
oncocytomas and five chromophobe renal cell carcinomas (chRCCs). 
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Supplementary Figure 2. Distribution of SMYD2 (A), SETD3 (B) and NO66 (C) 
expression levels in kidney confined RCC (pT1/pT2) and locally invasive RCC (pT3). 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Distribution of SMYD2 (A), SETD3 (B) and NO66 (C) 
expression levels in low Fuhrman grade (G1/G2) and high Fuhrman grade (G3/G4) 
clear cell and papillary Renal Cell Carcinoma.  
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Supplementary Figure 4. Distribution of SMYD2 (A) and SETD3 (B) mRNA 
expression levels in RCTs according to low and high protein expression assessed by 
immunohistochemistry (IHC). Representative IHC images for each group of protein 
expression. (** p<0.01). IHC combined score (S) = staining intensity x percentage of 
positive cells; low protein expression (S<4): tumors with less than 33% of stained cells 
or staining intensity lower than normal kidney; high protein expression (S≥4): tumors 
with at least 33% of cells stained with an intensity equal or higher than normal kidney. 
 
 
 
 
 
 
 
Supplementary Figure 5. Distribution of SMYD2 (A), SETD3 (B) and NO66 (C) 
expression levels in kidney confined RCC (pT1/pT2) and locally invasive RCC (pT3) in 
TCGA dataset (http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm. Accessed 
2015). 
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Supplementary Figure 6. Distribution of SMYD2 (A), SETD3 (B) and NO66 (C) 
expression levels in low Fuhrman grade (G1/G2) and high Fuhrman grade (G3/G4) 
clear cell and papillary Renal Cell Carcinoma patients’ samples from the TCGA dataset 
(http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm. Accessed 2015). 
 
 
  
CHAPTER 4. METHYLATION IN RENAL CELL TUMORS 
116 
 
 
 
Supplementary Table 1. Comparison of SMYD2, SETD3 and NO66 expression levels 
in kidney confined RCC (pT1/pT2) and locally invasive RCC (pT3).  
 
Expression 
[median (range)] 
pT1/pT2 (n=91) pT3 (n=29) Mann-Whitney test 
SMYD2 1074 (32-10190) 1066 (11-5550) p=0.67 
SETD3 214 (1.8-1439) 226 (6-1221) p=0.73 
NO66 399 (3-26363) 499 (2-2386) p=0.86 
 
 
 
 
 
 
 
 
Supplementary Table 2. Comparison of SMYD2, SETD3 and NO66 expression levels 
in low Fuhrman grade (G1/G2) and high Fuhrman grade (G3/G4) clear cell and 
papillary renal cell carcinoma.  
 
Expression 
[median (range)] 
G1/G2 (n=35) G3/G4 (n=45) Mann-Whitney test 
SMYD2 903 (32-3649) 625 (11-4159) p=0.045 
SETD3 184 (1.8-1380) 85 (6-849) p=0.021 
NO66 381 (3-26363) 236 (2-1719) p=0.05 
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Supplementary Table 3. Pathological stage (pT) and gene (SMYD2, SETD3, NO66) 
expression level as prognostic factors for renal cell carcinoma obtained by multivariate 
Cox regression analysis. 
Prognostic Factor 
Multivariate Analysis 
Hazard 
Ratio (HR) 
95% CI for HR 
Cox regression 
p value 
Disease Specific Survival    
pT § 8.408 2.169-32.590 0.002 
SMYD2 expression level * 4.777 1.344-16.973 0.016 
Subtype, Gender - - N.S. 
pT § 6.340 1.622-24.778 0.008 
SETD3 expression level * 5.491 1.403-21.495 0.014 
Subtype, Gender - - N.S. 
pT § 7.277 1.876-28.224 0.004 
NO66 expression level * 3.978 1.118-14.159 0.033 
Subtype, Gender - - N.S. 
Disease Free Survival    
pT § 3.939 1.264-12.271 0.018 
SMYD2 expression level * 10.912 2.939-40.511 <0.001 
Subtype, Gender - - N.S. 
pT §   0.092 
SETD3 expression level * 9.778 2.643-36.172 0.001 
Subtype, Gender - - N.S. 
pT §   0.050 
NO66 expression level * 6.220 1.868-20.709 0.003 
Subtype, Gender - - N.S. 
 
CI: Confidence Interval, N.S.: not-significant (p>0.05). 
§ 
Stage I / Stage II vs Stage III / Stage IV; 
reference group: pT1/pT2. * Reference group: high expression level. 
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Supplementary Table 4. Clinical and pathological data of patients included in 
TCGA dataset (http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm. 
Accessed 2015). 
 
  Normal Matched Tumor 
Number of patients, n  129 889 
Age, median (range) 61 (28-90) 60 (17-90) 
Gender, n (%)   
Male 87 (67.44%) 579 (66.94%) 
Female 42 (32.56%) 286 (33.06%) 
Histological subtype, n (%)    
Clear cell RCC 72 (55.81%) * 533 (59.96%) 
Papillary RCC 32 (24.81%) *  290 (32.62%) 
Chromophobe RCC 25 (19.38%) * 66 (7.42%) 
Pathological stage, n (%)    
pT1 52 (40.31%) * 468 (54.61%) 
pT2 25 (19.38%) *  123 (14.35%) 
pT3 48 (37.21%) * 251 (29.29%) 
pT4 4 (3.10%) * 15 (1.75%) 
Fuhrman grade, n (%) ¥   
1 1 (1.39%) * 13 (2.50%) 
2 28 (38.89%) * 228 (43.76%) 
3 28 (28.89%) * 205 (39.35%) 
4 15 (20.83%) * 75 (14.40%) 
RCC, Renal Cell Carcinoma. * For normal renal tissue, histological subtype, pathological stage 
and Fuhrman grade of the matched RCC is depicted. 
¥ 
Data available only for clear cell Renal 
Cell Carcinoma. 
 
 
 
 
  
CHAPTER 4. METHYLATION IN RENAL CELL TUMORS 
119 
 
 
Supplementary Table 5. Prognostic factors for TCGA dataset (http://tcga-
data.nci.nih.gov/tcga/dataAccessMatrix.htm. Accessed 2014) for each RCC subtype by Cox 
regression analysis. 
Prognostic Factor 
Univariate Analysis Multivariate Analysis 
HR 
95% CI for 
HR 
p value
¥
 HR 
95% CI for 
HR 
p value
¥
 
ccRCC       
Disease Specific Survival       
Pathological Stage
§
 4.35 3.14-6.02 <0.0001 2.74 1.86-4.04 <0.0001 
Metastasis(during follow-up)ⱷ 4.70 3.43-6.44 <0.0001 2.37 1.63-3.43 <0.0001 
SMYD2 expression level* 1.53 1.05-2.21 0.027   0.067 
SETD3 expression level* 2.16 1.59-2.95 <0.0001 1.77 1.29-2.42 <0.0001 
NO66 expression level*   0.389   0.749 
Gender
ᴪ
   0.838   0.460 
Disease Free Survival       
Pathological Stage
§
 8.97 1.39-57.70 0.021 8.97 1.39-57.70 0.021 
SMYD2 expression level*   0.212   0.305 
SETD3 expression level*   0.796   0.585 
NO66 expression level*   0.185   0.171 
Gender
ᴪ
   0.230   0.355 
pRCC       
Disease Specific Survival       
Pathological Stage
§
 5.26 2.57-10.76 <0.0001 3.57 1.61-7.95 0.002 
Metastasis(during follow-up)ⱷ 93.65 27.68-316.92 <0.0001 43.99 11.46-168.87 <0.0001 
SMYD2 expression level*   0.912   0.941 
SETD3 expression level* 2.84 1.43-5.63 0.003 2.11 1.00-4.45 0.051 
NO66 expression level* 8.00 2.66-24.05 <0.0001 6.49 2.00-21.11 0.002 
Gender
ᴪ
   0.230   0.097 
Disease Free Survival       
Pathological Stage
§
 7.78 2.34-25.89 0.001 7.25 2.19-24.03 0.001 
SMYD2 expression level*   0.777   0.967 
SETD3 expression level* 4.74 1.44-15.57 0.010 4.64 1.39-15.51 0.013 
NO66 expression level* 6.98 1.48-32.96 0.014   0.227 
Gender
ᴪ
   0.095   0.381 
chRCC 
a
       
Disease Specific Survival       
Pathological Stage
§
 6.69 1.73-25.95 0.006 11.86 1.38-101.81 0.024 
Metastasis(during follow-up)ⱷ 20.50 1.86-226.04 0.014   0.052 
SMYD2 expression level*   0.450   0.641 
SETD3 expression level* 7.22 1.37-37.94 0.020   0.303 
NO66 expression level*   0.484   0.600 
Gender
ᴪ
   0.396   0.171 
 
HR: Hazard Ratio; CI: Confidence Interval, n.s.: not significant. 
¥
Cox regression p value; significant when 
p<0.05. 
§
Stage I / Stage II vs Stage III / Stage IV; reference group: Stage I / Stage II. *Reference group: high 
expression level. ⱷReference group: Absence of metastasis. 
ᴪ
Reference group: Male. 
a
 Disease Free survival 
was not performed for chRCC due to insufficient available data. 
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Supplementary Table 6. SMYD2, SETD3 and NO66 expression in “GEO DataSet” 
(http://www.ncbi.nlm.nih.gov/gds. Accessed 2015), comprising eighteen patients, nine 
with oncocytoma and nine with chromophobe Renal Cell Carcinoma. Mann-Whitney 
was used for comparison between oncocytoma and chRCC. 
 
Expression 
[median (range)] 
Oncocytoma (n=9) chRCC (n=9) 
Mann-Whitney 
test 
SMYD2 [ID REF: 
212921_at] 
0.29 (0.27- 0.47) 0.44 (0.28 – 0.85) 0.031 
SMYD2 [ID REF: 
212922_s_at] 
24.9 (5.4 - 9373) 23.5 (10.5 - 8655) 1 
SETD3 [ID REF: 
229940_at] 
1033 (0.76 - 1192) 1205 (1.3 - 2612) 0.011 
NO66 [ID REF: 219526_at] 2889 (2234 - 3344) 3833 (2657 - 7663) 0.008 
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5.3. SETDB2 AND RIOX2 ARE DIFFERENTIALLY EXPRESSED 
AMONG RENAL CELL TUMOR SUBTYPES, ASSOCIATING WITH 
PROGNOSIS AND METASTIZATION 
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Abstract 
Increasing detection of small renal masses by imaging techniques, entails the need for 
accurate discrimination between benign and malignant renal cell tumors (RCTs) as well 
as among malignant RCTs, owing to differential risk of progression through 
metastization. Although histone methylation has been implicated in renal 
tumorigenesis, its potential as biomarker for renal cell carcinoma (RCC) progression 
remains largely unexplored. Thus, we aimed to characterize the differential expression 
of histone methyltransferases (HMTs) and histone demethylases (HDMs) in renal cell 
tumors (RCTs) to assess their potential as metastasis biomarkers. We found that 
SETDB2 and RIOX2 (encoding for an HMT and an HDM, respectively) expression levels 
was significantly altered in RCTs, and were further selected for validation by 
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quantitative RT-PCR in 160 RCTs. Moreover, SETDB2, RIOX2 and three genes encoding 
for enzymes involved in histone methylation (NO66, SETD3 and SMYD2), previously 
reported by our group, were quantified (RT-PCR) in an independent series of 62 clear 
cell renal cell carcinoma (ccRCC) to assess its potential role in ccRCC metastasis 
development. Additional validation was performed using TCGA dataset. SETDB2 and 
RIOX2 transcripts were found overexpressed in RCTs compared to renal normal tissues 
(RNTs), in oncocytomas vs. RCCs, with ccRCC and papillary renal cell carcinoma (pRCC) 
displaying the lowest levels. Low SETDB2 expression levels and higher stage 
independently predicted shorter disease-free survival. In our 62 ccRCC cohort, 
significantly higher RIOX2, but not SETDB2, expression levels were depicted in cases 
that developed metastasis during follow-up. These findings were not apparent in TCGA 
dataset. We concluded that SETDB2 and RIOX2 might be involved in renal 
tumorigenesis and RCC progression, especially in metastatic spread. Moreover, SETDB2 
expression levels might independently discriminate among RCC subgroups with distinct 
outcome, whereas higher RIOX2 transcript levels might identify ccRCC cases with more 
propensity to endure metastatic dissemination. 
 
Keywords: Kidney cancer, renal cell tumor, renal cell carcinoma, histone 
methyltransferase, SETDB2, RIOX2, biomarker, prognosis, metastasis 
 
Running title: SETDB2 and RIOX2 deregulation associates with renal cell tumor 
metastization. 
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Introduction 
Kidney cancer incidence is increasing 
worldwide, with 62,700 new cases and 
14,240 deaths estimated for 2016 1. 
Increasing incidence has been 
attributed to the rising number of 
incidental small renal tumours 
diagnosed due to widespread use of 
imaging techniques, as well as to 
ageing, obesity and smoking, which are 
known risk factors for the development 
of kidney cancer 2. Increased detection 
of small renal masses emphasises the 
need for accurate discrimination not 
only between benign and malignant 
RCTs, but also among malignant RCTs 
subtypes. Indeed, renal cell carcinomas 
(RCCs) more likely to behave 
aggressively and to develop metastases 
should be clearly distinguished from 
those that will probably have a more 
indolent growth and might be managed 
more conservatively 3, 4. Among RCCs, 
the most frequent are clear cell renal 
cell carcinoma (ccRCC), papillary renal 
cell carcinoma (pRCC) and 
chromophobe renal cell carcinoma 
(chRCC). Whereas ccRCC is the 
histotype that more frequently 
develops metastases, pRCC is more 
frequently multifocal and chRCC is 
mostly an indolent cancer that rarely 
develops metastases, although its 
differential diagnosis with oncocytoma, 
a benign tumour, might be 
challenging5. 
Metastasis is the foremost cause of 
cancer-related mortality, despite 
improvements in diagnosis, surgical 
techniques, patient care and adjuvant 
therapies. Biologic heterogeneity of 
tumour cells, as well as differences in 
metastatic tumour microenvironment 
at different sites may influence 
response to therapy 6. Thus, 
understanding pathogenesis of 
metastases at cellular and molecular 
level has become a major goal in cancer 
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research 6, 7. Indeed, management of 
metastatic renal cell carcinoma (mRCC) 
remains a major clinical challenge. 
Although median survival of patients 
with mRCC has been increasing due to 
therapeutic advances, specifically in 
antiangiogenic drugs and tyrosine-
kinase inhibitors (from approximately 
12 months with cytokine therapy to 
more than 26 months with VEGF 
inhibitors therapy) 8, 5-year survival for 
advanced kidney cancer was only 11.7% 
in the period 2007-2013 9. Albeit the 
proportion of patients with mRCC at 
diagnosis has declined, due to 
improved imaging techniques as well as 
more intense screening and incidental 
case ascertainment, a sizeable number 
of small RCCs (< 4cm diameter) may 
present renal capsule invasion, tumour 
thrombus or lymphatic and distant 
metastasis 3, 4, and their identification 
constitutes a major challenge. 
Altered epigenetic homeostasis has 
been implicated in tumorigenesis and 
epigenetic-based biomarkers may assist 
in diagnosis, prognostication and 
prediction of response to targeted 
therapy 10. Histone modifications and 
chromatin modulators, in particular, 
have been shown to play an important 
role in cancer progression 11. In RCC, 
certain histone modifications associate 
with progression-free survival and 
correlate with pathological 
characteristics of tumours 12. In 
addition, defects in epigenetic 
enzymes, involved in chromatin 
remodelling and packaging, have been 
implicated in development of RCTs, 
reflecting the role of these mechanism 
in renal tumorigenesis 13. Herein, we 
aimed to investigate the potential of 
HMTs and HDMs expression as 
biomarkers of metastatic progression in 
RCC, using two independent RCTs 
cohorts, complemented with external 
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validation in TCGA dataset. We selected 
SETDB2 (an HMT) and RIOX2 (an HDM), 
based on an extended characterization 
of histone methyltransferases in RCTs, 
previously reported by our group 14. 
Additionally, we also tested SMYD2 and 
SETD3 (both HMT), as well as NO66 
(HDM), previously evaluated in our first 
RCT cohort and TCGA dataset 14, in the 
second cohort comprising ccRCC with 
indolent (non-metastatic) and 
aggressive (metastatic) disease. 
 
 
Results 
Validation of RIOX2 and SETDB2 
expression in RCTs 
RIOX2 and SETDB2 expression levels 
were assessed by quantitative RT-PCR 
in a series of 160 RCTs and 13 RNTs. 
The results were fully concordant with 
those of the TaqMan® Array as both 
genes were significantly overexpressed 
in RCTs compared to RNTs (p<0.0001 
for SETDB2 and p<0.05 for RIOX2; 
(Figures 1A and 1B). Moreover, RIOX2 
and SETDB2 expression levels differed 
significantly between benign and 
malignant RCTs (Figures 1C and 1D), 
and among the four RCT subtypes 
(Table 1). Oncocytomas displayed the 
highest SETDB2 and RIOX2 expression 
levels, followed by chRCC (Figures 1E 
and 1F and Table 1).  
 
Table 1. Comparison of SETDB2 and RIOX2 
expression among renal normal tissue (RNT), 
renal cell tumors (RCT), renal cell carcinoma 
(RCC) and RCT histotypes. For histotype 
pairwise comparison, the values were 
statistically significant when p<0.0125 
(Bonferroni’s correction). 
 
 
 SETDB2 
(p value) 
RIOX2 
(p value) 
RNT vs RCT <0.001 <0.05 
RNT vs RCC 0.001 0.444 
Oncocytoma vs RCC <0.001 <0.001 
ccRCC vs pRCC 0.392 0.658 
ccRCC vs chRCC <0.001 <0.001 
ccRCC vs oncocytoma <0.001 <0.001 
pRCC vs chRCC <0.001 <0.001 
pRCC vs oncocytoma <0.001 <0.001 
chRCC vs oncocytoma <0.001 0.131 
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Figure 1. Expression levels of SETDB2 and RIOX2 in cohort#1. A: SETDB2 expression in renal cell tumors 
(RCTs) and renal normal tissues (RNTs) B: RIOX2 expression in renal cell tumors (RCTs) and renal normal 
tissues (RNTs) C: SETDB2 expression in benign tumors (oncocytoma) and malignant tumors (renal cell 
carcinoma [RCCs]); D: RIOX2 expression in benign tumors (oncocytoma) and malignant tumors (renal cell 
carcinoma [RCCs]); E: SETDB2 expression in renal cell tumors subtypes; F: RIOX2 expression in renal cell 
tumors subtypes. (****p<0.0001; **p<0.01; *p<0.05). 
 
Pairwise comparisons demonstrated 
that SETDB2 and RIOX2 expression 
levels significantly differed between 
chRCC and both pRCC and ccRCC, and 
between pRCC and both chRCC and 
oncocytoma. Furthermore, SETDB2 
transcript levels differed significantly 
between chRCCs and oncocytomas 
(Figures 1E and 1F and Table 1). 
 
SETDB2 and RIOX2 expression levels 
and clinicopathological correlates 
No significant differences in gender and 
age were apparent between patients 
and controls. In RCCs, no statistically 
significant associations were disclosed 
between SETDB2 and RIOX2 expression 
levels and Fuhrman or pathological 
stage categories. In RCTs, expression 
levels of both genes were significantly 
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Figure 2. Expression levels of SETDB2 (A) and RIOX2 (B) in clear cell renal cell carcinomas and papillary 
renal cell carcinomas (cohort#1) with or without metastasis (p<0.05). 
 
higher in females. Moreover, RIOX2 
expression levels significantly 
associated with patient’s age (p=0.015). 
In ccRCCs and pRCCs, SETDB2 
expression levels were significantly 
lower in patients that developed 
metastases (Figures 2A and 2B).  
 
SETDB2 and RIOX2 expression levels as 
prognostic markers 
The median follow-up of RCC patients 
was 175 months (range: 2-375 months). 
A total of 15 patients died from RCC 
during this period. In univariable 
analysis, higher pathological stage (pT3 
or higher) associated with shorter 
survival whereas gender, age, 
histological subtype and Fuhrman 
grade did not disclose any prognostic 
value within the available follow-up 
time. Disease-specific survival (DSS) 
analysis showed that low SETDB2 and 
RIOX2 levels were significantly 
associated with worse outcome (p<0.01 
and p<0.05 respectively; (Figures 3A 
and 3B). Concerning disease-free 
survival (DFS) analysis, low SETDB2 
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levels significantly associated with 
shorter time to disease progression 
(p<0.0001; Figure 3C). The same trend 
was observed for RIOX2, but statistical 
significance was not reached (p=0.055; 
Figure 3D). In this series, only one case 
with local recurrence presented distant 
metastasis before local recurrence 
developed, thus DFS is equivalent to 
metastasis-free survival in this case. In 
multivariable analysis, a final model 
including SETDB2 expression levels and 
pathological stage was predictive of 
disease-free survival. 
 
 
Figure 3. Kaplan-Meier estimated disease-specific survival curves and disease-free survival curves for 
SETDB2 (respectively A and C) and RIOX2 (respectively B and D). 
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Indeed, higher risk of disease 
progression was depicted for patients 
with higher pathological stage [HR: 3.03 
(1.16-7.80), p=0.024] and lower SETDB2 
expression levels [HR: 5.11 (1.72-
15.24), p=0.003]. 
 
RIOX2, SETDB2, SETD3, SMYD2 and 
NO66 expression and risk of 
metastization in ccRCC 
No significant differences were 
apparent for gender and age (p=0.570 
and p=0.402 respectively) between 
ccRCCs patients which developed 
metastases and those that did not 
(cohort #2). Furthermore, no 
statistically significant associations 
were disclosed between SETDB2 and 
RIOX2 expression levels and Fuhrman 
grade or pathological stage in this 
cohort. In this cohort, expression levels 
of SETD3, SMYD2 and NO66, which we 
have previously found to associate with 
shorter disease-specific and disease-
free survival 14, did not significantly 
differ between the two groups of ccRCC 
patients (Figures 4C, 4D and 4E). 
Concerning RIOX2 and SETDB2 
expression levels, only the former 
differed significantly between 
metastasized and non-metastasized 
ccRCCs (Figure 4B). 
 
RIOX2 and SETDB2 expression in RCC 
Patients from TCGA Dataset 
In TCGA dataset, significantly lower 
RIOX2 expression levels were found in 
RCC compared to RNT, contrarily to our 
results. Nevertheless, among RCCs, 
pairwise comparisons showed that 
RIOX2 expression levels were 
significantly higher in chRCCs compared 
to ccRCCs and pRCCs, paralleling our 
findings. In ccRCCs from TCGA
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Figure 4. Expression levels of SETDB2 (A), RIOX2 (B), SETD3 (C), SMYD2 (D) and NO66 (E) in clear cell 
renal cell carcinomas (cohort#2) with or without metastasis (p<0.05). 
 
database, no statistically significant 
difference was disclosed for RIOX2 
expression levels between the group of 
patients that developed metastases 
and those that did not. 
Concerning SETDB2, lower expression 
levels were depicted in RCC compared 
to RNT, as well. In line with our results, 
however, pairwise comparisons 
demonstrated that SETDB2 expression 
levels were significantly higher in 
chRCCs compared to ccRCCs and pRCCs, 
and expression levels significantly 
differed among subtypes. Considering 
only ccRCCs from TCGA database, no 
statistically significant difference was 
apparent for SETDB2 expression levels 
between the group of patients that 
developed metastases and those that 
did not, paralleling our results. 
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Discussion 
Due to the widespread use of imaging 
tests, the frequency of incidentally 
detected RCTs has significantly 
increased, consisting mainly of small 
and early stage tumours. However, as 
lymph node and distant metastases 
may occur even in small RCCs 15 and the 
latter constitute the main cause RCC-
related mortality 16, there is an unmet 
need for biomarkers capable of 
accurately discriminate tumours that 
will metastasize from those that will 
not, especially among pT1, which are 
the most amenable to nephron-sparing 
surgery. Because epigenetic-based 
biomarkers may assist in diagnosis, 
prognostication and prediction of 
response to targeted therapy 10, we 
hypothesized that histone 
modifications and chromatin 
modulators 11 might aid in the 
identification of RCCs more prone to 
recur and metastasize. Indeed, previous 
reports have shown that, in RCC, 
histone modifications are associated 
with pathological features and DFS 12, 
and defects in chromatin remodelers 
and chromatin packaging are 
implicated in RCT development 13. 
In this study, we focused mostly on 
RIOX2 and SETDB2 expression levels as 
candidate biomarkers for RCC 
prognostication. Whereas RIOX2 
encodes for an HDM, displaying high 
transcript or protein levels in RCC and 
several other cancers, associating with 
poor prognosis 17-24, SETDB2 encodes 
for an HMT involved in leukemogenesis 
15 but was not previously associated 
with solid tumors. These two genes 
were selected based on previously 
published array data from our team 14, 
which were confirmed through analysis 
of cohort #1 tissue samples. Indeed, 
both RIOX 2 and SETDB2 were found 
overexpressed in RCTs compared to 
non-paired normal renal tissues, 
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suggesting that their deregulation is 
associated with neoplastic 
transformation of renal parenchymal 
cells. Interestingly, renal oncocytomas 
displayed the highest RIOX2 and 
SETDB2 expression levels, significantly 
differing from RCCs. This result might 
be of practical value for distinction 
between oncocytoma and chRCC, 
especially the eosinophilic variant, as 
both histotypes display variable degree 
of morphological overlap, rendering 
differential diagnosis problematic, 
particularly in small core biopsies 25. 
Unexpectedly, when TCGA dataset was 
interrogated for RIOX2 and SETDB2 
expression in renal tissues, RCCs 
displayed significantly lower expression 
levels than normal renal tissues, 
contrarily to our findings in cohort #1. 
Nonetheless, the expression ranking 
among RCCs in TCGA paralleled our 
findings, with chRCC displaying the 
highest expression levels, compared to 
ccRCC and pRCC. This discrepancy 
might be related with the origin of the 
“normal renal tissue” analysed. Indeed, 
whereas in our study RNT samples 
derived from kidneys not harbouring 
RCC, those of TCGA dataset were 
collected from macroscopically normal 
looking areas of organs involved by 
RCC. As we have previously shown, 
these “paired” normal renal tissue 
samples disclose significant epigenetic 
alterations, that may precede 
neoplastic transformation 26. Thus, the 
results from cohort #1 and TCGA 
dataset analysis may not be directly 
comparable. 
A major goal of this study was to 
ascertain the prognostic value of RIOX2 
and SETDB2 expression levels in RCCs. 
Whereas, in univariable analysis, lower 
RIOX2 and SETDB2 expression levels 
associated with worse DSS, only lower 
SETDB2 levels associated with worse 
DFS. Interestingly, among standard 
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clinicopathological parameters, only 
stage reached statistical significance. In 
multivariable analysis, however, only 
low SETDB2 expression and stage 
retained statistical significance, 
suggesting that assessment of SETDB2 
expression might add relevant 
prognostic information for the 
management of RCC patients. Although 
a previous report has associated higher 
RIOX2 immunoexpression with shorter 
DSS in RCC 17, these results are not 
directly comparable with ours as we did 
not assess protein expression and the 
proportion of RCC subtypes also 
differed. Indeed, in our series, survival 
analysis results were mostly influenced 
by ccRCC and pRCC, which displayed 
the lowest expression levels among 
RCCs. Moreover, RIOX2 overexpression 
has been associated with worse 
prognosis in oesophageal cancer 24 but 
with favourable outcome in lung cancer 
27, emphasizing that the biological and 
clinical impact of RIOX2 expression is 
strongly dependent on the primary 
location and the specific cancer type. 
Because DFS was analogous to 
metastasis-free survival in cohort #1, 
we looked for differences in SETDB2 
expression levels among tumours with 
and without metastasis. Interestingly, 
we found significantly lower SETDB2 
expression in ccRCC and pRCC (the 
more clinically aggressive histotypes) 
with metastasis. However, when we 
attempted to validate these findings is 
an independent cohort comprising 
ccRCC with and without metastasis 
(cohort #2) and in ccRCCs from TCGA 
dataset, no significant differences were 
disclosed. Nonetheless, significantly 
higher RIOX2 transcript levels were 
depicted in ccRCC that developed 
metastasis during follow-up compared 
to matched ccRCC without metastasis, 
suggesting that RIOX2 expression might 
be a biomarker of progression 
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(metastization) in ccRCC. Interestingly, 
high RIOX2 expression levels have been 
associated with development of 
lymphatic or distant metastasis in bile 
duct, gastric and pancreatic carcinomas 
22, 23, 28. In TCGA dataset, however, no 
differences in RIOX2 expression levels 
were apparent between ccRCCs that 
developed metastases and those that 
did not. These discrepancies might be 
due to differences in follow-up time 
and enrolment criteria, as we excluded 
from analysis cases that presented 
metastasis at diagnosis and only 
analysed cases in which metastases 
developed after curative-intent surgical 
treatment. Although we further 
evaluated three genes encoding for 
histone modifying enzymes (SMYD2, 
SETD3 and NO66) previously shown to 
be associated with worse prognosis in 
RCC 14 in cohort #2, their expression 
levels did not significantly differ 
between ccRCC with and without 
metastasis. 
Although our findings might be limited 
by the sample size, it should be 
emphasized that the most frequent 
histotypes are represented, whereas in 
many studies only ccRCC cases have 
been included. Moreover, survival 
analysis is based on long-term follow-
up data, including two patient cohorts 
and TCGA dataset. Finally, although 
candidate biomarkers were previously 
identified in array-based analysis, 
validation in independent patient’s 
series was undertaken, whereas several 
previous studies proposing array-based 
biomarkers for RCC, have not validated 
them or have just performed validation 
in limited series of patients 29-32, 
precluding the assessment of its clinical 
usefulness. 
In conclusion, our results suggest that 
SETDB2 and RIOX2 might be involved in 
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renal tumorigenesis and RCC 
progression, especially in metastatic 
spread. Moreover, SETDB2 expression 
levels might independently discriminate 
among RCC patient subgroups with 
distinct outcome, whereas higher 
RIOX2 transcript levels might identify 
ccRCC cases with more propensity to 
endure metastatic dissemination. 
 
 
Materials and Methods 
Patients and Sample Collection  
A series of 160 RCTs (cohort #1) 
comprising 40 cases of each subtype 
(ccRCC, pRCC, chRCC and oncocytoma) 
was prospectively collected from 
patients consecutively diagnosed and 
submitted to nephrectomy at the 
Portuguese Oncology Institute of Porto 
(IPO Porto). As controls, 13 renal 
normal tissue (RNT) samples were 
procured from patients submitted to 
nephro-ureterectomy due to upper 
urinary tract urothelial carcinoma, not 
involving the renal parenchyma. All 
tissues were immediately frozen and 
stored at -80ºC. Sampling of more than 
70% of malignant cells was confirmed 
using two slides stained with 
hematoxylin and eosin (H&E) taken 
before and after frozen section 
collection for RNA extraction. Relevant 
clinical data was retrieved from clinical 
charts.  
An independent series of 62 ccRCCc 
(cohort #2) comprising 31 ccRCCs that 
have developed metastasis and 31 
ccRCCs that did not progress, matched 
for gender, age, tumor size, grade and 
stage at diagnosis, was also retrieved 
from the archives. Tissue samples were 
prepared as described above.  
This study was approved by the ethics 
committee of IPO Porto (CES-IPOPFG-
EPE 518/10). 
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RNA Extraction 
For RNA extraction, samples were 
suspended in TRIzol® reagent 
(Invitrogen™, Carlsbad, CA, USA; Cat. 
#15596018) and chloroform (Merk 
Milipore, Darmstadt, Germany; 
Cat.#MCX10601) was added after the 
cells were lysed. RNA concentrations 
and purity ratios were determined 
using a NanoDrop ND-1000 
spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA). 
Samples were then stored at -80ºc. 
 
HMT and HDM selection 
Selection of candidate HMTs and HDMs 
was based on the results of previously 
reported custom made TaqMan® Array 
96-Well expression plates (Applied 
Biosystems®, Foster City, CA, USA; 
Cat#4391528) 14. SMYD2, SETD3 and 
NO66 had been previously validated 
and found to be associated with shorter 
disease-specific and disease-free 
survival 14. Additionally, SETDB2 and 
RIOX2 expression also displayed high 
fold variation between RCTs and RCCs, 
as well as between chRCC and 
oncocytomas, and were thus selected 
for further validation. Both presented 
higher expression in RCT compared to 
RNT, as well as in oncocytomas than in 
chRCC. 
 
Validation of Selected Enzymes  
RIOX2 and SEDTB2 mRNA expression 
levels were firstly evaluated in cohort 
#1. Subsequently, RIOX2, SETDB2, 
SMYD2, NO66 and SETD3 expression 
was assessed in cohort #2.  
For validation in cohort #1, 300ng of 
mRNA was reverse transcribed and 
amplified using TransPlex®Whole 
Transcriptome Amplification Kit (Sigma-
Aldrich®, St.Louis, MO, United States) 
with subsequent purification using 
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QIAquick PCR Purification Kit (QIAGEN, 
Germany), according to manufacturer’s 
instructions. RIOX2 and SETDB2 mRNA 
levels were evaluated using TaqMan® 
Gene Expression Assays [Applied 
Biosystems®, Foster City, CA, USA; 
Hs99999908 m1 (GUSβ), Hs99999901 
s1 (18s), Hs01126272 m1 (SETDB2), 
Hs00262155 m1 (RIOX2)] according to 
manufacturer’s instructions. For each 
sample, expression levels were 
normalized using two internal 
reference gene, GUSβ and 18s, 
according to the formula: target gene 
relative expression = target gene 
expression level / ((GUSβ expression 
level + 18s expression level) / 2). Each 
plate included multiple non-template 
controls and serial dilutions of a cDNA 
Human Reference Total RNA (Agilent 
Technologies, La Jolla, CA, USA; 
Cat.#750500) to construct a standard 
curve.  
For validation in cohort #2, 1 μg of total 
RNA was reverse transcribed using the 
High Capacity cDNA Reverse 
Transcription kit according to the 
manufacturer’s instructions. RIOX2, 
SETDB2, SMYD2, NO66 and SETD3 
mRNA levels were evaluated using 
TaqMan® Gene Expression Assays 
[Applied Biosystems®, Foster City, CA, 
USA; Cat.#4331182 Hs00220210 m1 
(SMYD2), Hs00260120 m1 (SETD3), 
Hs02743012 s1 (NO66), Hs99999908 
m1 (GUSβ), Hs99999901 s1 (18s), 
Hs01126272 m1 (SETDB2), Hs00262155 
m1 (RIOX2) ] according to 
manufacturer’s instructions. For each 
sample, expression levels were 
normalized using two internal 
reference gene, GUSβ and 18s, 
according to the formula: target gene 
relative expression = target gene 
expression level / ((GUSβ expression 
level + 18s expression level) / 2). Each 
plate included multiple non-template 
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controls and serial dilutions of a cDNA 
Human Reference Total RNA (Agilent 
Technologies, La Jolla, CA, USA; 
Cat.#750500) in order to construct a 
standard curve. 
 
TCGA Dataset Analysis in pRCC, chRCC 
and ccRCCs Patients  
The Cancer Genome Atlas (TCGA) 
dataset was interrogated for data on 
RIOX2 and SETDB2 expression and 
clinical information, when available, 
from ccRCCs, pRCCs and ccRCCs 
patients. All expression data from 
samples hybridized at the University of 
North Carolina, Lineberger 
Comprehensive Cancer Center, using 
Illumina HiSeq 2000 RNA Sequencing 
version 2 analysis, were downloaded 
from TCGA data matrix (http://tcga-
data.nci.nih.gov/tcga/tcgaDownload.jsp
). This dataset included 533 ccRCC, 290 
pRCC and 66 chRCC. The provided value 
was pre-processed and normalized 
according to “level 3” specifications of 
TCGA (see 
http://cancergenome.nih.gov/dataport
al/ for details). Biospecimen Core 
Resources (BCRs) provided the clinical 
data of each patient. This data is 
available for download through TCGA 
data matrix (http://tcga-
data.nci.nih.gov/tcga/dataAccesMatrix.
htm). 
 
Statistical Analysis 
Non-parametric tests were used to 
ascertain statistical significance of 
comparisons among groups. Kruskal-
Wallis test (KW) was used for 
comparisons among multiple groups 
and Mann-Whitney U test (MW) was 
used for pairwise comparisons. The 
prognostic significance of 
clinicopathological variables (age, 
gender, histological subtype, 
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pathological stage, Fuhrman grade) and 
HMTs and HDMs expression levels was 
assessed by constructing disease-
specific and disease-free survival curves 
using the Kaplan-Meier method with 
log-rank test (univariable test). The 
expression levels of SETDB2 and RIOX2 
were classified as low or high based on 
the cutoff value of 25th percentile for 
SETDB2 expression and 75th percentile 
for RIOX2. A Cox-regression model 
comprising the different variables 
(multivariable test) was also 
constructed. For this analysis, the 120 
RCC patients from cohort #1 were 
included. 
Statistical significance was set at 
p<0.05. Bonferroni correction was 
applied for pairwise comparisons 
following multiple groups’ analyses. 
Statistical analysis was performed using 
SPSS software for Windows, version 
22.0 (IBM-SPSS Inc., Chicago, IL, USA), 
and graphs were built using GraphPad 
Prism 6.0 software for Windows 
(GraphPad Software Inc., La Jolla, CA, 
USA). 
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6.1.GENERAL DISCUSSION 
 
The last years were fertile in novel data on genetic and epigenetic alterations in renal 
cell tumors, and especially in integrative, multi-level approaches to data interpretation, 
fueled by TCGA project [1-4], but not limited to it [5-8]. These approaches allowed for 
a more comprehensive picture of renal carcinogenesis, reflecting its complexity and 
corroborating the relevance of epigenetic alterations, mostly histone modulators’ 
alterations [9-11]. Other epigenetic alterations have been also recurrently reported in 
renal cell carcinomas, including promoter methylation [12-18] and microRNAs 
deregulation [19-22]. Additional description of distinct epigenetic alterations in 
different histotypes of renal cell tumors reflects the potential of DNA methyation [23, 
24] and miRNA profile [25-27] as promising diagnostic biomarkers. 
However, most of the genome-wide approaches that identified these differentially 
methylated genes were usually not followed by extensive validation in independent 
series [17, 23, 24] using more sensitive methodologies. Moreover, most of the first 
discovery series were predominantly or exclusively composed of clear cell renal cell 
carcinoma [12-17, 19-22], the most frequent renal cell carcinoma subtype, although 
this trend has been changing [6, 28, 29]. 
In the scope of this Thesis, quantitative methylation specific polymerase chain reaction 
(QMSP) was used to assess methylation levels of genes reported to be differentially 
methylated among renal cell tumor subtypes [23, 24, 30]. QMSP is a sensitive and 
robust technique, that could be performed in most molecular pathology labs, suitable 
to study DNA methylation of specific regions [31]. Thus, a panel based on the 
methylation of specific gene regions could be an economically viable and efficient 
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methodology to detect specific methylation profiles associated with renal malignancy 
and/or specific RCT histotypes, with the additional advantages that, as DNA is more 
stable than RNA, assays detecting DNA alterations are often more robust; DNA 
methylation is a more homogeneous target than gene mutations; and DNA 
methylation is an early event in renal tumorigenesis [31-33]. 
A two-gene promoter methylation panel (OXR1&MST1R) that distinguishes normal 
kidney from renal cell tumors, and clear cell renal cell carcinoma from other renal cell 
tumors with high sensitivity and specificity, was here described. Thus, it might be a 
useful diagnostic biomarker for clear cell renal cell carcinoma. Its potential would be 
probably greater as ancillary tool for renal mass biopsy examination, considering the 
limitations that most methylation-based diagnostic biomarkers present when assessed 
in biological fluids [34-36]. The diagnostic performance of this panel in detection of 
malignancy and clear cell renal cell carcinoma was better than most similar panels 
reported thus far [37]. Although not directly comparable due to distinct methodology, 
this methylation panel results are globally equivalent to methylation array-based assay 
panels, which are more demanding [38, 39]. For the identification of oncocytoma, a 
miRNA panel comprising miRNA-141 and miRNA-200b proved to be more sensitive and 
specific than the referred methylation panel, in the same cohort of cases [40], 
suggesting that distinct types of alterations might be more suitable to identify distinct 
RCT subtypes. Indeed, it is not surprising that methylation-based biomarkers display 
lower sensitivity and specificity in the distinction between chromophobe renal cell 
carcinoma and oncocytoma, as methylation array studies reported methylation rates 
usually not higher than 35% in chromophobe renal cell carcinoma and oncocytoma 
[24], and globally a lower number of genes were found to be methylated in 
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chromophobe renal cell carcinoma and oncocytoma compared to clear cell renal cell 
carcinoma [3, 6, 24]. Conversely, higher promoter methylation frequency correlated 
with higher stage and grade tumors in the TGGA dataset [1], and therefore is not 
surprising that grade 3&4 clear cell renal cell carcinomas in our cohort presented 
higher OXR1 methylation levels. 
We also explored the biological and functional effect of promoter methylation on 
MST1R gene expression in kidney tumors. MST1R is a C-MET proto-oncogene family 
receptor tyrosine kinase, involved in a pathway frequently altered in renal cell 
carcinoma, especially papillary but also clear cell renal cell carcinoma [1, 2, 4]. MST1R 
promoter methylation pattern was described to be involved in distinct transcript 
variant expression [41]. This might parallel the increasing importance recognized for 
the methylation pattern of specific gene transcription regulation [42, 43], but at the 
promoter level. Although we could associate promoter methylation pattern with the 
predicted mRNA expression pattern only in clear cell carcinoma cell lines, we purpose 
that in in vivo renal tumors, additional factors might be involved in the regulation of 
variant expression. However, MST1R expression was associated with prognosis, most 
probably reflecting its relation to a frequently altered cellular pathway in renal cell 
carcinoma [1, 2, 4]. 
Histone methyltransferase and histone demethylase expression was also approached 
to distinguish between chromophobe renal cell carcinoma and oncocytoma, by using a 
PCR-based array as screening test. This revealed that most histone methyltransferases 
and demethylases presented altered expression between renal normal tissue and renal 
cell tumors, and between oncocytoma and chromophobe renal cell carcinoma, 
probably related to the role of histone alterations in renal tumorigenesis. 
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We validated five of the most differentially expressed enzymes – SMYD2, SETD3, 
NO66, SETDB2 and RIOX2 – in a large series (cohort#1) of 160 renal cell tumors, with 
concordant results for chromophobe renal cell carcinoma and oncocytoma. Validation 
results also revealed similar expression profiles for clear cell and papillary renal cell 
carcinoma, and for chromophobe renal cell carcinoma and oncocytoma, mirroring the 
tumor cell of origin within the nephron, respectively proximal tubule and distal tubule. 
This pattern was also described in multiplatform integrative analysis, suggesting that 
each tumor expression pattern might reflect the cell of origin as well as additional 
genetic and epigenetic alterations [3, 4]. TCGA cases were also used as a validation 
independent cohort, portraying similar results for clear cell, papillary and 
chromophobe renal cell carcinoma (oncocytomas are not represented in TCGA). 
SMYD2, SETD3, NO66 and SETDB2 expression level were associated with prognosis in 
renal cell carcinoma in multivariable analysis, each one of them providing additional 
information to tumor stage. This might reflect histone alteration role not as driver 
event, but as modulator of tumor aggressiveness. In fact, our data also suggest that 
RIOX2 might be involved in metastasis development. Additionally, mutations in histone 
modifying enzymes [1, 44], as well as some histone marks [10], as acetylation [45] and 
methylation (H3K4 [44], H3K27 [46], H3K9 [47], H3K36 [48]) have been associated with 
renal cell carcinoma prognosis. Altered expression of histone modifying enzymes, also 
observed in other studies [49, 50], might be another layer of histone deregulation with 
relevance for renal cell carcinoma progression. 
Despite being promising prognostic biomarkers for renal cell carcinoma, validated in 
two large independent series, it would be valuable to further explore the biological 
function of SMYD2, SETD3, NO66 and SETDB2, as well as performing additional 
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assessment in specific populations and clinical contexts. Moreover, renal cell 
carcinoma tumor heterogeneity [51, 52] should also be taken into account, especially 
when only limited samples are available.  
 
 
 
6.2. GENERAL CONCLUSIONS AND PERSPECTIVES 
 
Epigenetic alterations constitute promising biomarkers for clinical management of 
renal cell tumors, paralleling its involvement in renal tumorigenesis. These alterations, 
mostly promoter methylation and miRNA expression, might be useful as diagnostic 
biomarkers. Histone modifying enzymes might constitute useful prognostic markers in 
renal cell carcinoma. 
The promising diagnostic and prognostic biomarkers here described, despite the 
validation performed, require additional assessment in large multicenter trials to 
support clinical implementation 
For the diagnostic biomarkers, assessment of their clinical value as ancillary tool in 
renal mass biopsy specimens and/or formalin-fixed paraffin-embedded specimens 
would be valuable, as it could aid in rendering a more accurate diagnosis, especially if 
the diagnostic performance remained robust in small specimens, as well as in liquid 
biopsies. 
It would also be relevant to assess the prognostic performance of these histone 
modifying enzymes in the context of targeted therapy in clinical series of patients with 
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metastatic renal cell carcinoma, as well as their performance as biomarkers predictive 
of response to therapy.  
Moreover, the functional role of these histone modifying enzymes should be evaluated 
in renal cell carcinoma, to assess their potential as epigenetic drug targets or agents. 
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